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ABBREVIATIONS AND DEFINITIONS 
 
ATP  Adenosine triphosphate 
AUC  Area under concentration-time curve 
AUC0-∞ Area under concentration-time curve from time 0 to infinity 
AUC0-t  Area under concentration-time curve from time 0 to t 
AUCc  Area under concentration-time curve in control phase 
AUCi  Area under concentration-time curve in inhibited phase 
CAR  Constitutive androstane receptor 
Ch,u/Cp,tot Ratio of unbound hepatic to plasma total concentration 
CI  Confidence interval 
CL  Clearance 
CL/F  Oral clearance 
Cavg,t  Average concentration during time 0-t 
Cmax  Maximum concentration 
CYP  Cytochrome P450 
DNA  Deoxyribonucleic acid 
EDTA  Ethylenediaminetetraacetic acid 
EMA  European Medicines Agency 
F  Oral bioavailability 
FDA  Food and Drug Administration 
FDCL  Fractional decrement in oral clearance 
FG  Extent of bioavailability across the intestinal wall 
fm  Fraction metabolised by an enzyme 
fm,CYP2C8 Fraction metabolised by CYP2C8 
ft,OATP1B1 Fraction transported by OATP1B1 
fu  Fraction unbound 
GR  Glucocorticoid receptor 
HLM  Human liver microsomes 
HMG CoA 3-Hydroxy-3-methylglutaryl coenzyme A 
HUCH  Helsinki University Central Hospital 
[I]  Inhibitor concentration 
IC50  Inhibitor concentration supporting half of the maximal inhibition 
[I]g  Inhibitor concentration in the intestine 
[I]h  Inhibitor concentration in the liver 
[I]p,u  Plasma unbound inhibitor concentration 
IVIVE  In vitro – in vivo extrapolation 
kdeg  First-order degradation rate constant of an enzyme 
kdeg,gut  First-order degradation rate constant of an enzyme in the intestine 
kdeg,hep  First-order degradation rate constant of an enzyme in the liver 
ke  Elimination rate constant 
Ki  Inhibitor concentration supporting half of the maximal inhibition 
kinact  Maximal rate of inactivation 
KI Inhibitor concentration supporting half of the maximal rate of enzyme 
inactivation 
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Km   Michaelis-Menten kinetic constant 
kobs  Apparent rate of inactivation 
MBI  Mechanism-based inhibition 
MRP2  Multidrug resistance-associated protein 2 
MDMA 3,4-dimethylenedioxymetamphetamine (ecstasy) 
MIC  Metabolic inhibitory complex / metabolic intermediate complex 
mRNA  Messenger ribonucleic acid 
NADPH Nicotinamide adenine dinucleotide phosphate, reduced 
NTCP  Sodium-dependent taurocholate cotransporting polypeptide 
OAT  Organic anion transporter 
OATP  Organic anion-transporting polypeptide 
OCT  Organic cation transporter 
P-gp  P-glycoprotein 
PBPK  Physiologically based pharmacokinetic 
Ph. Eur. European Pharmacopoeia 
PPARα Peroxisome proliferator activated receptor alpha 
PXR  Pregnane X receptor 
r  Partition ratio 
r2  Coefficient of determination 
[S]  Substrate concentration 
SD  Standard deviation 
SLCO  Solute carrier organic anion transporter 
SNP  Single nucleotide polymorphism 
t  Time 
t1/2  Elimination half-life 
TDI  Time-dependent inhibition 
tmax  Time to maximum concentration 
UGT  Uridine-5’-diphosphoglucuronosyltransferase 
v  Rate of metabolite formation 
Vd  Volume of distribution 
Vmax  Maximum velocity  
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Drug-drug interactions may cause serious, even fatal clinical consequences. Therefore, it is 
important to examine the interaction potential of new chemical entities early in drug 
development. Mechanism-based inhibition is a pharmacokinetic interaction type, which 
causes irreversible loss of enzyme activity and can therefore lead to unusually profound and 
long-lasting consequences. The in vitro – in vivo extrapolation (IVIVE) of drug-drug 
interactions caused by mechanism-based inhibition is challenging. Consequently, many of 
these interactions have remained unrecognised for many years. 
 
The concomitant use of the fibrate-class lipid-lowering agent gemfibrozil increases the 
concentrations of some drugs and their effects markedly. Even fatal cases of rhabdomyolysis 
occurred in patients administering gemfibrozil and cerivastatin concomitantly. One of the 
main mechanisms behind this effect is the mechanism-based inhibition of the cytochrome 
P450 (CYP) 2C8 enzyme by a glucuronide metabolite of gemfibrozil leading to increased 
cerivastatin concentrations. Although the clinical use of gemfibrozil has clearly decreased 
during recent years, gemfibrozil is still needed in some special cases. To enable safe use of 
gemfibrozil concomitantly with other drugs, information concerning the time and dose 
relationships of CYP2C8 inhibition by gemfibrozil should be known. 
 
This work was carried out as four in vivo clinical drug-drug interaction studies to examine the 
time and dose relationships of the mechanism-based inhibitory effect of gemfibrozil on 
CYP2C8. The oral antidiabetic drug repaglinide was used as a probe drug for measuring 
CYP2C8 activity in healthy volunteers. In this work, mechanism-based inhibition of the 
CYP2C8 enzyme by gemfibrozil was found to occur rapidly in humans. The inhibitory effect 
developed to its maximum already when repaglinide was given 1-3 h after gemfibrozil intake. 
In addition, the inhibition was shown to abate slowly. A full recovery of CYP2C8 activity, as 
measured by repaglinide metabolism, was achieved 96 h after cessation of gemfibrozil 
treatment. The dose-dependency of the mechanism-based inhibition of CYP2C8 by 
gemfibrozil was shown for the first time in this work. CYP2C8 activity was halved by a 
single 30 mg dose of gemfibrozil or by twice daily administration of less than 30 mg of 
gemfibrozil. Furthermore, CYP2C8 activity was decreased over 90% by a single dose of 900 
mg gemfibrozil or twice daily dosing of approximately 100 mg gemfibrozil. In addition, with 
the application of physiological models to the data obtained in the dose-dependency studies, 
the major role of mechanism-based inhibition of CYP2C8 in the interaction between 
gemfibrozil and repaglinide was confirmed. 
 
The results of this work enhance the proper use of gemfibrozil and the safety of patients. The 
information related to time-dependency of CYP2C8 inhibition by gemfibrozil may also give 
new insights in order to improve the IVIVE of the drug-drug interactions of new chemical 
entities. The information obtained by this work may be utilised also in the design of clinical 





Drug-drug interactions may have serious clinical consequences, and therefore, the potential of 
new chemical entities causing or being a victim of an interaction should be carefully studied. 
The interaction potential can be assessed using in vitro (laboratory), in vivo (animal and 
human study) and in silico (computational) methods. In early drug development, in vitro 
methods are used for assessing the metabolic pathways and for screening the interaction 
potential (Pelkonen et al., 2005). In vitro - in vivo extrapolation (IVIVE) is used for predicting 
the clinical drug-drug interactions of the compound. In case of signs of interaction potential 
based on in vitro studies or IVIVE, drug interaction studies are carried out. 
 
Two decades ago, gemfibrozil, a fibric acid derivative, was a promising agent for the 
treatment of hyperlipidaemia. It was shown to reduce triglyceride levels and increase high-
density lipoprotein cholesterol levels, and to reduce the number of coronary events in patients 
with or without a history of coronary disease. However, no reduction in the total mortality in 
gemfibrozil-treated subjects could be seen (Frick et al., 1987). Gemfibrozil seemed safe and 
well-tolerated, but turned out to cause serious drug-drug interactions. E.g., patients 
administering concomitantly cerivastatin and gemfibrozil developed myopathy more often 
than when using the drugs separately (Furberg and Pitt, 2001). Approximately one third of the 
cerivastatin treated patients who developed fatal rhabdomyolysis had used gemfibrozil 
concomitantly. 
 
The interaction potential of gemfibrozil is complex. Gemfibrozil has been shown to increase 
the exposure to several drugs, e.g., repaglinide, cerivastatin, rosiglitazone, pioglitazone, 
montelukast and loperamide in humans (Backman et al., 2002; Niemi et al., 2003a; Niemi et 
al., 2003b; Jaakkola et al., 2005; Niemi et al., 2006; Karonen et al., 2010). According to the 
current understanding, gemfibrozil can inhibit both drug metabolism and transport, thereby 
affecting the elimination of drugs from the body. Although the complex interaction potential 
of gemfibrozil has restricted its clinical use, it still has a role in the management of 
hyperlipidaemia in certain cases (Loomba and Arora, 2010).  
 
The interaction potential of gemfibrozil is utilised in the examination of the metabolic profile 
and interaction potential of new drug candidates. Gemfibrozil is recommended as CYP2C8 
inhibitor both in in vitro and in vivo studies in drug development by regulatory authorities 
(FDA, 2006; EMA, 2010). The inhibition of the CYP2C8 enzyme by gemfibrozil is mainly 
based on mechanism-based inactivation of CYP2C8 by the glucuronide metabolite of 
gemfibrozil (Shitara et al., 2004; Ogilvie et al., 2006). Both the inhibition mechanism and the 
fact that it is caused by a phase II metabolite of a drug make this interaction unique 
(VandenBrink and Isoherranen, 2010). 
 
The mechanism-based nature of CYP2C8 inhibition by gemfibrozil has been earlier reported 
and the inhibition mechanism has been kinetically characterised in in vitro studies (Ogilvie et 
al., 2006). In addition, the effect of gemfibrozil on many CYP2C8 substrate drugs has been 
studied in vivo in humans (Backman et al., 2002; Niemi et al., 2003a; Niemi et al., 2003b; 
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Jaakkola et al., 2005; Niemi et al., 2006; Ogilvie et al., 2006). In a recent study, the effect of 
gemfibrozil on CYP2C8-mediated metabolism in humans persisted at least for 12 h after 
discontinuation of gemfibrozil (Tornio et al., 2008a). It created us to examine the persistence 
of the CYP2C8 inhibition by gemfibrozil in more detail. It could be hypothesised also that the 
interaction would initiate fairly slowly. Firstly, gemfibrozil is a mechanism-based inhibitor. 
Secondly, the interaction between gemfibrozil and CYP2C8 substrates is mainly based on a 
phase II metabolite of an orally administered drug. To examine this issue, we studied the 
onset time of mechanism-based CYP2C8 inhibition by gemfibrozil in humans. 
 
In addition to time-dependency, the dose-dependency of the mechanism-based inhibition of 
CYP2C8 by gemfibrozil has not been known. Only a few studies concerning dose-
dependency of mechanism-based inhibitors in humans have been published, and none of them 
concerned gemfibrozil. In this thesis work, based on studies using gemfibrozil at different 
dose levels new data concerning the interaction mechanism was obtained. The time- and dose-
dependency information of mechanism-based inhibition obtained in this work may guide the 
clinical use of gemfibrozil and CYP2C8 substrate drugs, and aid the development process of 
new therapeutic drugs in the future. 
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REVIEW OF THE LITERATURE 
 
 
1. Drug metabolism and pharmacokinetic interactions 
 
Drugs are foreign compounds to the human body. Most of them are relatively hydrophobic 
and need to undergo biotransformation in order to terminate their therapeutic effect and 
facilitate their elimination from the body (Murray, 1997). Biotransformation of drugs, which 
protects the human body from intoxications (Remmer, 1965; Remmer, 1970), can be divided 
into two major groups of reactions (Meyer, 1996). Phase I reactions, e.g., oxidation, 
reduction, hydrolysis and hydration, introduce or expose a functional group in the drug 
molecule. This functional group is subsequently conjugated, often with a highly water soluble 
moiety such as glucuronic or sulfonic acid, during phase II metabolism. In addition to the 
protective detoxification function, biotransformation may also cause formation of active 
intermediate species, which, in certain situations, may elicit tissue lesions (Remmer, 1970; 
Brodie et al., 1971; Murray, 1997). 
1.1. Cytochrome P450 enzymes  
 
Cytochrome P450 (CYP) enzymes are the most important phase I enzymes. They are a 
superfamily of haem containing polypeptide chains, which catalyse primarily oxidative 
metabolism of drugs and other xenobiotics (Wrighton and Stevens, 1992; Brown et al., 2008). 
In addition to drug and other xenobiotic biotransformation, CYP enzymes have key roles in 
physiological processes, e.g., bile acid biosynthesis, cholesterol metabolism as well as steroid 
and vitamin D biosynthesis and metabolism (Nebert and Russell, 2002; Estabrook, 2003). 
CYP enzymes are mainly located in the liver and in the gut, which are the main organs for 
drug metabolism, but they are found in other tissues as well (Krishna and Klotz, 1994). 
 
Cytochrome P450 was detected in the 1950’s and first thought to be one single enzyme, 
which was associated with the metabolism of drugs and steroids (Nebert and Russell, 2002). 
Later, it was understood that several different CYP enzymes exist. As the number of different 
CYP enzymes increased, a nomenclature system was considered necessary. The nomenclature 
system introduced in 1987 arranges CYP enzymes into families and subfamilies based on the 
amino acid sequences (Nelson et al., 1996). Enzymes that share ≥ 40% identity belong to a 
family designated by an Arabic numeral (e.g., CYP2) and enzymes that share ≥ 55% identity 
comprise a subfamily designated by a letter (e.g., CYP2C). Individual enzymes are separated 
from other members in the same subfamily with a unique Arabic number at the end (e.g., 
CYP2C8). The CYP families participating in the metabolism of drugs and other xenobiotics 
are almost exclusively CYP1, CYP2 and CYP3 (Nebert and Russell, 2002). CYP2C8 is 
presented in more detail in section 8. 
 
The human CYP superfamily consists of altogether 57 genes. The genes of the CYP enzymes 
are written in italics, and the reference allele with efficient metabolic activity is named with 
*1 (e.g., CYP2C8*1) (Nebert and Russell, 2002). Allelic variants, which may have different 
metabolic activities, are named with different numbers and/or letters, e.g., *2 or *1B. By 
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definition, allelic variants are considered genetic polymorphisms, if they occur in ≥ 1% of the 
population (Nelson, 1999). 
 
In addition to structure, CYP enzymes differ from each other, e.g., by expression site and 
quantity, substrate specificity and susceptibility to different enzyme inhibitors and inducers 
(Guengerich, 1992). CYP enzymes are located in the endoplasmic reticulum of the cells 
(Meyer, 1996). The basic catalytic cycle of CYP enzymes is shown in Figure 1 (Hollenberg, 
1992; Lin and Lu, 1998). 
 
 
Figure 1. Basic catalytic cycle of cytochrome P450 enzymes. RH, drug; NADPH, reduced 
nicotinamide adenine dinucleotide phosphate; NADP+, nicotinamide adenine dinucleotide phosphate; 
e-, electron; ROH, oxidised drug. 
 
1.2. Pharmacokinetic drug interactions 
 
Main mechanisms of pharmacokinetic interactions include physicochemical interactions, 
plasma protein binding related interactions, as well as interactions due to changes in enzyme 
and transporter activity (Kanamitsu et al., 2000b). Both increase and decrease in enzyme and 
transporter activities can occur, due to induction and inhibition, respectively. Pharmacokinetic 
interaction mechanisms can lead to changes in the absorption, distribution, metabolism and 
excretion of the drugs. Inhibition of CYP enzymes is one of the main mechanisms leading to 
clinical drug-drug interactions (Lin and Lu, 1998; Pelkonen et al., 2008). 
 
2. Enzyme inhibition 
 
Drug metabolism plays an important role in vivo, and its inhibition may cause severe 
consequences. The inhibition of drug metabolism can lead to decreased clearance (CL), and 
therefore, increased exposure to the parent compound. This may lead to enhanced drug 
efficacy and even fatal toxicity or, in the case of prodrugs, to decreased therapeutic effect (Lin 
and Lu, 1998; Pelkonen et al., 1998; Pelkonen et al., 2008). The consequences of enzyme 
inhibition in vivo may vary due to many reasons, e.g., the inhibitor drug (e.g., inhibition type, 
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inhibitor potency, dosing scheme), the victim drug (e.g., the importance of the inhibited 
enzyme for metabolism, presence of alternative metabolic routes, therapeutic index) and the 
patient (e.g., concomitant diseases, concomitant medications, variability in drug metabolism). 
 
The area under the concentration-time curve (AUC) reflects the in vivo exposure to the drug. 
The fold increase in the AUC of the parent drug in the inhibited state compared to control 
phase (AUCinhibited/AUCcontrol) can be used as a simple method for the quantification of the 
enzyme inhibition in vivo (Ito et al., 2004). With few exceptions, changes in exposure of less 
than 2-fold typically occur without clinical consequences, whilst an increase of the exposure 
to a drug by 2-fold or more is considered a threshold for greater concern (Obach, 2009). 
However, the therapeutic index of the victim drug affects the clinical relevance of the enzyme 
inhibition markedly, and even a small change in exposure may be relevant with drugs having 
a narrow therapeutic range. 
 
Based on the reversibility of the inhibitory effect, CYP enzyme inhibition can be divided into 
reversible, quasi-irreversible and irreversible inhibition (Hollenberg, 2002). 
2.1. Reversible inhibition 
 
Reversible inhibition arises from the competition of the inhibitor and the substrate of the 
metabolising enzyme. Reversible enzyme inhibition is believed to involve only the first step 
of the CYP catalytic cycle (binding to the ferric form of the enzyme). The inhibitor is non-
covalently bound to the enzyme, and can dissociate from it making the inhibition reversible. 
Reversible inhibition actually disappears soon after the removal of the inhibitory agent, e.g., 
due to clearance of the drug from the body or due to filtration, centrifugation or 
electrophoresis in experimental conditions. Both the onset and offset of reversible inhibition 
are rapid, governed mainly by the inhibitor concentration at the enzyme site. The potency of 
the inhibitor can be described with the inhibitor concentration needed for half of the maximal 
inhibition (Ki). 
 
The velocity of the CYP mediated enzymatic reactions in vitro can usually be described using 










where v is the rate of metabolite formation, Vmax is the maximum velocity, Km is the 
Michaelis-Menten constant describing the substrate concentration at half-maximal velocity, 
and [S] is the substrate concentration. 
 
Known metabolic index reactions can be used in the assessment of the activity of different 
CYPs in vitro. A decrease in the formation of the expected metabolites, or a decrease in the 
depletion of the parent compound in the index reactions in the presence of the compound 
under examination serves as an indicator of enzyme inhibition (Pelkonen and Turpeinen, 
2007; Emoto et al., 2010). Some index reactions for the main human drug metabolising CYPs 
are presented in Table 1. 
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Table 1. Index reactions for CYP enzyme activity (Guengerich, 1990; Bjornsson et al., 2003; Testino 
and Patonay, 2003; Walsky and Obach, 2004; Pelkonen et al., 2005; Turpeinen et al., 2005b). 
CYP 
enzyme 
Index reaction CYP 
enzyme 
Index reaction 
CYP1A2 Caffeine N-demethylation 
Melatonin 6-hydroxylation 
Phenacetin O-deethylation 
CYP2C19 (S)-mephenytoin 4’-hydroxylation 
Omeprazole 5’-hydroxylation 
CYP2A6 Coumarin 7-hydroxylation CYP2D6 Bufuralol 1’-hydroxylation 
Dextromethorphan O-demethylation 
CYP2B6 Bupropion hydroxylation CYP2E1 Chlorzoxazone 6-hydroxylation 
N,N-dimethylnitrosoamine N-demethylation 
CYP2C8 Amodiaquine N-deethylation 
Paclitaxel 6α-hydroxylation 
CYP3A4 Midazolam 1’-hydroxylation 
Testosterone 6β-hydroxylation 








Reversible inhibition can be divided into subcategories of competitive, noncompetitive and 
uncompetitive inhibition by the inhibitory mechanism. 
 
Competitive inhibition. In competitive inhibition, the inhibitor prevents the binding of the 
substrate to the active site of the enzyme, i.e., the inhibitor and the substrate compete for the 
same binding site. This is the most common form of reversible inhibition affecting drug 























where [I] is the inhibitor concentration (Segel, 1975). This type of inhibition can be overcome 
by increasing the concentration of the substrate. 
 
Noncompetitive inhibition. In noncompetitive inhibition, the inhibitor and the substrate bind 
to different sites of the enzyme, and the inhibitor has no effect on the binding of the substrate 
to the enzyme. However, the complex formed by the enzyme, inhibitor and substrate is 
nonproductive. The enzyme kinetics in noncompetitive inhibition can be described according 
to the equation below (Segel, 1975): 
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Increasing the substrate concentration does not decrease the effect of this inhibition type. 
Noncompetitive inhibition is seen less frequently than competitive inhibition in drug 
metabolism.  
 
Uncompetitive inhibition. In uncompetitive inhibition, the inhibitor does not bind to the free 
enzyme, but binds to the substrate-bound enzyme making the enzyme-substrate-inhibitor 
complex unproductive. This type of inhibition is seldomly seen in drug metabolism. The 
enzyme kinetics in uncompetitive inhibition can be described according to the following 
equation (Segel, 1975): 
 
[ ]


















In addition to the types presented above, also mixed-type reversible inhibition can occur. The 
changes in the kinetic constants in different subtypes of reversible inhibition are shown in 
Table 2 (Fowler and Zhang, 2008). 
 
Table 2. Changes in the kinetic constants in different types of reversible inhibition. 
Inhibition type Change in Vmax Change in Km 
Competitive - ↑ 
Mixed competitive/noncompetitive ↓ ↑/↓ 
Noncompetitive ↓ - 
Uncompetitive ↓ ↓ 
Vmax, maximum velocity; Km, Michaelis-Menten kinetic constant 
 
2.2. Quasi-irreversible and irreversible inhibition 
 
Quasi-irreversible and irreversible inhibitions require at least one catalytic cycle of the 
enzyme to produce reactive intermediate species that modify the enzyme and cause loss of 
enzyme function.  
 
In irreversible inhibition, the victim enzyme catalyses the inhibitor into an active species, 
which, prior to its release from the active site, inactivates the enzyme. The inactivated enzyme 
is thereby prevented from catalysing its reaction permanently. This phenomenon usually 
results from the formation of a covalent bond between the inhibitor and the enzyme 
(Silverman, 1995). 
 
In quasi-irreversible CYP inhibition, or metabolic inhibitory complex (MIC) formation, a 
covalent bond is not produced, but a pair of electrons is donated from the inhibitor leading to 
sequestration of the enzyme to a functionally inactive state. Quasi-irreversible inhibition can 
be reversed in experimental conditions, e.g., by incubation with highly lipophilic drugs that 
displace the metabolic intermediate from the active site of the enzyme, by irradiation at 400-
500 nm, or by ferricyanide (Ullrich and Schnabel, 1973; Dickins et al., 1979), but is 
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irreversible in physiological conditions and is therefore indistinguishable from the 
pharmacokinetic impacts of irreversible inhibition in vivo (Riley et al., 2007). 
 
The phenomena of quasi-irreversible and irreversible inhibitions depending on the mechanism 
of the inhibited enzyme are called mechanism-based inhibition (MBI). In addition to 
mechanism-based enzyme inhibition, the reactive intermediate species produced by the 
enzyme may lead to organ toxicity such as hepatotoxicity induced by tienilic acid or 
troglitazone (Brodie et al., 1971; Ortiz de Montellano and Correia, 1983; Hollenberg, 1992; 
Cohen et al., 1997; Walgren et al., 2005; Masubuchi and Horie, 2007). 
 
3. Mechanism-based inhibition 
3.1. History and clinical relevance 
 
Mechanism-based inhibitors, also called “suicide inhibitors” and “Trojan horse inactivators”, 
are substrate molecules for the target enzyme, which in the process of catalytic conversion are 
changed into intermediates or products that inactivate the enzyme (Rando, 1984). This 
phenomenon detected in the late 1960’s (Helmkamp et al., 1968) and initially used in 
enzymology is particularly common in CYP-mediated biotransformations (Jones and Hall, 
2002). In mechanism-based inhibition the inactivator irreversibly alters the enzyme and 
removes it permanently from the pool of active enzyme. Synthesis of enzyme is needed for 





Figure 2. Changes in enzyme activity in mechanism-based inhibition in vivo. 
 
 
As the in vivo enzyme activity after mechanism-based inhibition can be regained only by de 
novo synthesis of the protein, its consequences can be more profound and persist longer than 
those of reversible inhibition. In fact, among the drugs causing pharmacokinetic interactions, 
mechanism-based inhibitors represent several of those agents causing interactions of the 
greatest magnitude (Venkatakrishnan et al., 2007). 
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The observation made in the 1980’s that the effects of the narcotic agent alfentanil were 
prolonged when patients had used the antibacterial agent erythromycin concomitantly was 
first shown to be due to the inhibition of alfentanil metabolism (Bartkowski et al., 1989), and 
later the mechanism was specified to be a mechanism-based inhibition of CYP3A4 by 
erythromycin (Periti et al., 1992). Similarly, the accumulation of caffeine in healthy 
volunteers treated concomitantly with antiasthmatic drug furafylline was first understood to 
be caused by the inhibition of caffeine metabolism by furafylline (Tarrus et al., 1987), and 
only later furafylline was shown to be a mechanism-based inhibitor of CYP1A2 (Kunze and 
Trager, 1993). 
 
The first reports of fatal clinical drug-drug interactions understood to be caused by the 
mechanism-based inhibition of drug metabolising enzymes were from 15 Japanese cancer 
patients who died of toxic effects of 5-fluorouracil during concomitant administration of 5-
fluorouracil prodrugs and the antiviral drug sorivudine. Sorivudine was later shown to be a 
mechanism-based inhibitor of dihydropyrimidine dehydrogenase, an enzyme responsible for 
5-fluorouracil metabolism (Okuda et al., 1997). 
 
Since then many clinically important drugs have been shown to be mechanism-based 
inhibitors of drug metabolising enzymes (Jones et al., 1999). The development of otherwise 
promising drugs has been stopped due to mechanism-based inhibition, and even approved 
drugs have been withdrawn from the market because of it. E.g., the development of 
furafylline was stopped early due to the mechanism-based inhibition of CYP1A2, and the 
calcium-channel blocker mibefradil was withdrawn from the market shortly after introduction 
to medical practice in 1998 due to the mechanism-based inhibition of CYP3A causing severe 
drug-drug interactions (Mullins et al., 1998; Backman et al., 1999; Prueksaritanont et al., 
1999; Tucker et al., 2001). Many important drugs have been identified as mechanism-based 
inhibitors of CYP enzymes, but have been preserved in clinical use with an understanding and 
careful management of this property. Examples of drugs, which are or have been in clinical 
use, and are mechanism-based inhibitors of CYP enzymes, are provided in Table 3. 
 
In addition, other compounds than therapeutic agents, e.g., industry chemicals, illicit drugs 
(e.g., 3,4-dimethylenedioxymetamphetamine (MDMA; ecstasy)), and natural compounds in 
food and herbal medicines (e.g., flavonoids bergamottin and 6’,7’-dihydroxybergamottin in 
grapefruit juice and glabridin in licorice root) can inactivate enzymes by this mechanism 
(Halmes et al., 1997; Lown et al., 1997; Schmiedlin-Ren et al., 1997; Wu et al., 1997; Guo et 
al., 2000; de la Torre et al., 2004; Heydari et al., 2004).  
 
Mechanism-based inhibition affecting human drug metabolism takes mainly place in the gut 
and the liver, which are the main organs responsible for drug metabolism, but it has also been 








Table 3. Examples of drugs with mechanism-based inhibition potential of CYP enzymes. 
Drug Therapeutic use Inactivated CYP 
enzyme 
 Reference(s) 
Clarithromycin Antibacterial CYP3A4 (Franklin, 1991; Mayhew et 
al., 2000) 
Clopidogrel Antithrombotic CYP2B6 and 
CYP2C19 
(Richter et al., 2004; 
Turpeinen et al., 2005a) 
Diltiazem Cardiovascular CYP3A4 (Ma et al., 2000; Rowland 
Yeo and Yeo, 2001) 
Disulfiram Alcoholism CYP2E1 (Kharasch et al., 1993) 
Domperidone Anti-emetic CYP3A4 (Chang et al., 2010) 
Erythromycin Antibacterial CYP3A4 (Franklin, 1991; Periti et al., 
1992) 
Ethinylestradiol Contraceptive CYP3A4* (Guengerich, 1988; Lin et 
al., 2002) 
Fluoxetine Antidepressant CYP3A4 (Mayhew et al., 2000) 
Fluticasone Anti-inflammatory 
(glucocorticoid) 




Anti-lipidaemic CYP2C8 (Ogilvie et al., 2006) 
Gestodene Contraceptive CYP3A4* (Guengerich, 1990) 
Imatinib Antineoplastic CYP3A4 (Filppula et al., 2011a) 
Isoniazid Antitubercular CYP1A2, CYP2A6, 
CYP2C8, CYP2C19 
and CYP3A4 
(Wen et al., 2002b; Polasek 
et al., 2004) 
Lapatinib Antineoplastic CYP3A4 (Teng et al., 2010) 
Lopinavir Antiviral CYP3A4 (Ernest et al., 2005) 
Mibefradil Cardiovascular CYP3A4 (Prueksaritanont et al., 
1999) 
Noscapine Antitussive CYP2C9 and 
CYP3A4 
(Fang et al., 2010) 
Omeprazole Treatment of gastro-
oesophageal acidity 
CYP2C19 (Paris et al., 2008; Ogilvie et 
al., 2011) 
Paroxetine Antidepressant CYP2D6 (Bertelsen et al., 2003) 
Ritonavir Antiviral CYP3A4 (Ernest et al., 2005) 
Rofecoxib Non-steroidal anti-
inflammatory drug 
CYP1A2 (Karjalainen et al., 2006) 
Saquinavir Antiviral CYP3A4 (Ernest et al., 2005) 
Ticlopidine Antithrombotic CYP2B6 and 
CYP2C19 
(Ha-Duong et al., 2001; 
Richter et al., 2004; 
Turpeinen et al., 2005a; 
Obach et al., 2007) 
Troleandomycin Antibacterial CYP3A4 (Franklin, 1991; Periti et al., 
1992) 
Verapamil Cardiovascular CYP3A4 (Ma et al., 2000; Wang et 
al., 2004) 
Zileuton Antiasthmatic CYP1A2 (Lu et al., 2003) 
Zolpidem Hypnotic CYP3A* (Polasek et al., 2010) 









3.2. Chemical mechanisms, kinetics and criteria 
 
Mechanism-based inhibition of CYP enzymes can result from an irreversible modification of 
the haem, the protein or both the haem and the protein. The modification can occur by the 
following chemical mechanisms (Zhang et al., 2008):  
 
1) the inhibitor binds covalently to the enzyme apoprotein (e.g., CYP3A4 
inactivation by grapefruit juice constituents) 
2) the inhibitor binds covalently to the prosthetic haem (e.g., CYP3A4 inactivation 
by gestodene) or 
3) the inhibitor chelates or coordinates with the haem (e.g., CYP3A4 inactivation by 
macrolide antibiotics (Mayhew et al., 2000)).  
 
Many mechanism-based inhibitors may inactivate their victim enzymes by more than one 
mechanism (Kent et al., 2001). Chemical structures associated with mechanism-based 
inhibition include, e.g., substituted imidazoles, furan rings, thiophenoles and acetylenes 
(Rock, 2008). The kinetics between the enzyme and the inhibitor in mechanism-based 
inhibition can be described as presented in Figure 3. 
 
    
 
Figure 3. Kinetics between enzyme (E) and inhibitor (I) in mechanism-based inhibition. The initial 
step that combines the inhibitor and the free enzyme is reversible. The micro constants kon, koff, k2, k3 
and k4 describe the reaction velocities. 
 
Mechanism-based inhibition can be described by the kinetic constants maximal inactivation 
rate (kinact) and the inactivation constant (KI). The ratio of the end product release to enzyme 
inactivation is termed as the partition ratio (r) (Walsh et al., 1978). For mechanism-based 
inhibition, it can be described as k3/k4. The most dedicated mechanism-based inhibitor would 
therefore have a partition ratio of 0, that is, every turnover of the inhibitor would produce an 
inactivated enzyme (Kalgutkar et al., 2007). 
 




3) substrate protection 
4) irreversibility 
5) inactivator stoichiometry 
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6) involvement of a catalytic step 
7) inactivation prior to release of active species. 
 
Since their introduction, the criteria have been specified and argued based on later research 
results. The current understanding of the criteria for mechanism-based inhibition is presented 
below: 
 
1) Time-dependency. The inhibitory effect of the compound becomes larger when increasing 
the in vitro incubation time or prolonging the dosing period in vivo. It is important to note that 
time-dependent inhibition and mechanism-based inhibition are not synonyms; mechanism-
based inhibition is just one form of time-dependent inhibition. Time-dependent inhibition can 
also occur due to other mechanisms, e.g., due to the formation of metabolites with a stronger 
inhibitory potential than the parent compound has or due to the so called slow binding 
inhibition (Zhang et al., 2008).  
 
2) Saturation. The rate of inactivation increases when the inhibitor is added, until all enzyme 
molecules are saturated. After that, no further increase in the inactivation rate can be 
observed, i.e., saturation kinetics of the inactivation can be seen. This phenomenon has later 
been nominated as pseudo first-order kinetics (Zhou et al., 2005b).  
 
3) Substrate protection. As mechanism-based inhibitors bind to the active site of the 
enzyme, the addition of substrates or competitive reversible inhibitors binding to the same site 
will protect the enzyme from inactivation. This criterion has later been questioned by the 
findings that alternate substrates in some cases accelerate, rather than protect, the inactivation 
of the victim enzyme (Masubuchi et al., 2002; Polasek et al., 2006).  
 
4) Irreversibility. The enzyme activity cannot be restored by dialysis or filtration. The 
criterion of irreversibility is fulfilled at least by the mechanism-based inhibitors producing a 
covalent bond to the enzyme.  
 
5) Inactivator stoichiometry. The number of inactivator molecules to inactivated enzymes 
should show a 1:1 stoichiometry, i.e., one inactivator molecule should be attached per enzyme 
active site. However, this criterion is not fulfilled in the case of multimeric enzymes with 
nonfunctional catalytic sites.  
 
6) Involvement of a catalytic step. The unreactive compound needs first to be catalysed by 
the victim enzyme into a reactive form which is able to destroy the enzymatic activity. The 
involvement of the catalytic step and the fact that the inhibitor must therefore be acceptable 
by the enzyme as a substrate may be one reason for the suggestion that mechanism-based 
inhibitors may exhibit stronger enzyme specificity than reversible inhibitors. Other 
inactivating compounds being reactive already before a catalytic step by the victim enzyme 
will not fulfil this criterion, and are therefore not considered mechanism-based inhibitors. 
 
7) Inactivation prior to release of active species. The enzyme inactivation must occur prior 
to the release of the active species. It must be shown that the active species produced by the 
enzyme does not first dissociate from the enzyme and then return to inactivate the enzyme. 
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In addition to these 7 original criteria by Silverman, mechanism-based inhibitors of CYP 
enzymes need to fulfil also the following criteria: 
 
8) NAPDH-dependent inactivation. The co-factor needed in CYP catalysed reactions, 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) is needed also for the 
inactivation. The system needs to be catalytically competent, and metabolism needs to be 
occurring (Rock, 2008). 
 
9) Lack of protection by exogenous nucleophiles / reactive oxygen species scavengers. 
The inactivation is not protected by exogenous nucleophiles (e.g., thiols, amines or cyanide) 
or reactive oxygen species scavengers (e.g., reduced glutathione, catalase or superoxide 
dismutase) (Fontana et al., 2005). 
 
4. Evaluation of enzyme inhibition in drug development 
 
In drug development, the prediction of drug-drug interactions in clinical use is essential 
(Pelkonen et al., 2005). In vitro testing of the inhibition of drug metabolism has extensively 
been used for the prediction of clinical drug-drug interactions since the mid-1990s (Polasek 
and Miners, 2007).  
 
The kinetic values obtained from the in vitro studies of a chemical entity and an 
understanding of the inhibitor concentrations in clinical use ([I]) form the basis for this in 
vitro – in vivo extrapolation (IVIVE) process for interactions based on enzyme inhibition (Ito 
et al., 2002). The most relevant concentration for the inhibition of hepatic drug metabolism 
would be the unbound concentration of the inhibitor in the hepatocytes at the enzyme site 
(Pelkonen and Turpeinen, 2007). Due to ethical reasons, this information is not achievable. 
Due to the time needed for the drug to reach an equilibrium between blood and hepatocytes, 
as well as a possible active influx or efflux transport of the drug the hepatic drug 
concentrations may well differ from drug concentrations in plasma (Ito et al., 1998). 
However, some concentration is needed for the extrapolations. At least average plasma 
concentration (Cavg), maximum plasma concentration (Cmax), estimated maximum 
concentrations at the hepatic inlet and more complicated constructs of inhibitor concentration 
changing over time have been used as surrogates of inhibitor concentration at the enzyme site 
(Ito et al., 1998; Kanamitsu et al., 2000b; Tonn et al., 2009; Zhang et al., 2009). The use of 
estimated free portal vein Cmax, especially by eliminating false negative predictions, has 
worked best for reversible inhibitors, while the use of free systematic Cmax has provided the 
best estimates for mechanism-based inhibitors (Obach et al., 2007; Obach, 2009). In addition 
to the issues related to the selection of the concentration used, the impact of plasma protein 
binding in IVIVE is controversial. 
 
In vitro inhibition cocktail assays have been developed for a rapid screening of the inhibition 
of major human CYPs (Testino and Patonay, 2003; Walsky and Obach, 2004; Turpeinen et 
al., 2005b; Tolonen et al., 2007; Sevior et al., 2010). The results from these assays can be 
used to guide further decisions on the fate of the compounds (Turpeinen et al., 2005b; Lahoz 
et al., 2008). However, standard approaches are required to confirm these results. 
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4.1. Prediction of the clinical importance 
 
The assessment of the inhibition potential for reversible inhibitors is based on the [I]/Ki ratio 
(Tucker et al., 2001). A value of < 0.1 usually indicates a low risk of interaction and a value 





Figure 4. Assessment of inhibition potential of reversible inhibitors based on the [I]/Ki ratio. 
 
 













where AUCi is the area under concentration-time curve in inhibited phase and AUCc is the 
area under concentration-time curve in control phase. In order to forecast the interaction 
potential between the reversible inhibitor and the substrate detailed information is required 
concerning the substrate metabolism by the enzyme. This can be expressed as the fraction 
metabolised by the inhibited enzyme (fm). With the use of substrate specific fm the predictions 
of clinical drug-drug interactions have been significantly improved. The fm can be estimated 
by several methods. For those drugs which are metabolised by polymorphically expressed 
CYPs such as CYP2C9, CYP2C19 and CYP2D6, pharmacokinetic studies can be carried out 
in subjects representing various genotypes. For drugs metabolised by other than 
polymorphically expressed enzymes, radiolabelled drug metabolism studies and metabolism 
studies with specific enzyme inhibitors can be performed. Obtaining the fm can be difficult, 
and the reliability of the obtained values can be questionable due to considerable 
interindividual variability (Venkatakrishnan et al., 2007).  
 
The estimates of the fm can provide guidance related to the need of further studies. If human in 
vivo data indicate that CYP enzymes contribute > 25% to the total clearance of a drug, further 
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studies are needed (Huang et al., 2008). In order to achieve an accurate prediction of the 
interaction potential the evaluation of the metabolism of a new chemical entity should be 
continued as long as the sum of the contribution rates of each elimination pathway is almost 
one (typically more than 0.7) (Hisaka et al., 2010).  
 
The drug-drug inhibition potential of a reversible inhibitor can be estimated by the following 


























For drugs with considerable intestinal metabolism (e.g., CYP3A4 substrate drugs), the 
incorporation of intestinal enzyme inhibition improves the predictions. However, the 
estimation of the inhibitor concentrations at the enzyme site in the gut ([I]g) is difficult. 
Furthermore, since drugs are frequently metabolised by several CYPs, the metabolism may 
shift to alternative metabolic pathways, when a single CYP is inhibited. The incorporation of 
parallel pathways of metabolism has been shown to improve the quantitative predictions of 
drug-drug interactions based on in vitro data (Ito et al., 2005; Brown et al., 2006). Several 
important factors are needed to take into account, when the clinical importance of drug-drug 
interactions is predicted (Table 4). 
 
Table 4. Examples of aspects to be considered in IVIVE of drug-drug interactions. 
Inhibitor related aspects In vitro kinetic constants of the inhibitor 
 Inhibitor concentration used in the predictions 
 Changes of inhibitor concentration over time 
 Active transport 
 Parallel interaction mechanisms 
 Inhibitory/inductive metabolites 
 Protein binding 
 
Substrate related aspects Substrate fm 
 Parallel pathways of metabolism 
 Protein binding 
 Extraction ratio 
 Therapeutic index 
 
Experimental design related aspects In vitro system used 
 In vitro to in vivo system differences 
 
Target dosage related aspects (both inhibitor and  Doses 
substrate) Routes of administration 
 Duration of treatments 
 Timing and order of administration 
 
Target population related aspects Interindividual variability 
 Age-related differences 
 Ethnic differences 
 Concomitant diseases 
 Concomitant treatments 
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Predictions made by the basic IVIVE techniques presented above can be refined by 
physiologically based pharmacokinetic (PBPK) modelling. With PBPK modelling, e.g., the 
changes in drug concentrations over time in vivo, and the extent of bioavailability across the 
intestinal wall (FG) can be taken into account (Obach et al., 2006; Wang, 2010; Rowland Yeo 
et al., 2011). In addition, models taking several interaction mechanisms simultaneously into 
account have been developed (Rowland Yeo et al., 2011). However, the prediction of 
interactions of a compound causing multiple effects may be difficult, at least because of the 
uncertainty of the relationships of the mechanisms in vivo (Fahmi et al., 2008; Fahmi et al., 
2009). 
 
Currently, the most advanced techniques of IVIVE perceive also the population variability, 
e.g., in CYP enzyme expression and activity, in the predictions, and are therefore 
recommended in drug-drug interaction risk assessment. PBPK modelling is not considered to 
replace clinical studies, but can now already be used to design these studies. With PBPK 
modelling the number of clinical studies and subjects participating in them can be reduced. 
This is particularly relevant for certain populations such as children and patients with renal 
impairment. With successful PBPK modelling clinical drug-drug interaction studies may 
become confirmatory rather than exploratory, as was in the past. PBPK modelling is currently 
a rapidly developing research area. In addition to the variability in the population in general, 
specific aspects, e.g., ethnicity, specific pharmacokinetic features of children and patients 
with renal or liver impairment can be taken into account in the modelling of pharmacokinetics 
and drug-drug interactions (Rostami-Hodjegan and Tucker, 2007; Grime et al., 2009; Jamei et 
al., 2009a; Jamei et al., 2009b; Johnson et al., 2009; Johnson et al., 2010; Johnson and 
Rostami-Hodjegan, 2010). 
 
5. Specific features of the evaluation of mechanism-based inhibition 
 
In addition to the principles presented above, for mechanism-based inhibition the maximal 
inactivation rate by the inhibitor (kinact) and the first-order turnover degradation rate of the 
inhibited enzyme (kdeg) are essential for successful IVIVE. In fact, in the case of IVIVE using 
only the values sufficient for reversible inhibition, the interactions based on mechanism-based 
inhibition can be seriously underestimated, or even failed to be recognised (Venkatakrishnan 
and Obach, 2007). 
 
In basic in vitro inhibition tests, the changes in the kinetic constants Vmax and Km in the case 
of mechanism-based inhibition are similar to the changes seen with reversible noncompetitive 
inhibitors (Table 2). Therefore, based on data obtained from in vitro studies designed for the 
assessment of reversible inhibition, mechanism-based inhibitors can be incorrectly referred to 
as reversible noncompetitive inhibitors (Lin and Lu, 1998). 
 
The experiments needed to define the essential inactivation constants are laborious, and 
therefore, in early drug development with many possibilities of failures and cessation of 
further development, a step-wise approach in the assessment of the interaction potential is 
considered reasonable. 
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5.1. IC50 shift assays 
 
Traditionally, the first-line screening methods of mechanism-based inhibition include the 
demonstration of a time-dependent shift in the concentration supporting half the maximal 
inhibition (IC50) in vitro (Lim et al., 2005; Obach et al., 2007). In this method, an 
enhancement of the inhibitory potency (i.e., a decrease in the IC50) is shown to occur during 
pre-incubation with human liver microsomes (or specific recombinant CYP isoforms) and 
NADPH prior to incubation with the enzyme-selective index substrate. The incubation 
process will result in a leftward shift in the IC50 curve as shown in Figure 5. The IC50 curves 
of reversible inhibitors without and with preincubation will remain distinguishable, or even 
show a rightward shift due to the consumption of the inhibitor during the preincubation 
(Venkatakrishnan and Obach, 2007). It is important to note that a decrease in the IC50 shows 
just time-dependent inhibition, but does not indicate the compound to be a mechanism-based 
inhibitor. Methods for showing the IC50 shift easily, e.g., with only two different 





Figure 5. The principle of IC50 shift assays for showing time-dependent enzyme inhibition. The 
enzyme activity with different inhibitor concentrations with incubation without NADPH (black dots) 
and with incubation with NADPH (black squares) is plotted against the inhibitor concentration. A 
lower enzyme activity is observed with the same inhibitor concentration with incubation with NADPH 
compared to that without NADPH (vertical arrow). The concentration supporting half of the maximal 




The probe substrate used has been shown not to significantly affect the results of the in vitro 
assessment of mechanism-based inhibition, at least for CYP3A (Watanabe et al., 2007). The 
in vitro system, however, which is used for the evaluation of time-dependent inhibition, may 
affect the results for at least some compounds. Human liver microsomes and recombinant 
CYPs (expressed in E. coli) were not equivalent enzyme sources when the time-dependency 
of the inhibition of CYP enzymes by tricyclic antidepressants were examined. Nortriptyline 
showed a time-dependent inhibition in the recombinant CYP2C19 and CYP3A4, but not of 
the enzymes of human liver microsomes (Polasek and Miners, 2008). 
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In addition to the demonstration of the IC50 shift, techniques of covalent-binding assays with 
radiolabelled drugs and progress curve analysis methods can be used for a rapid screening of 
mechanism-based inhibition in early drug development (Evans et al., 2004; Salminen et al., 
2011). 
5.2. Kinetic constants 
 
After an observed leftward shift in the IC50 curves, in vitro tests for the calculation of the 
kinetic constants are usually carried out. The experimental approach is to perform a 
preincubation of the enzyme together with co-factors and with different inhibitor 
concentrations for varying times, followed by a further incubation of a dilution of the reaction 
mixture with a probe substrate to assess the degree of enzyme inactivation (Grimm et al., 
2009). A dilution of the reaction mixture at least in the ratio of 1:10 is performed in order to 
prevent a further inactivation of the enzyme during the probe substrate incubation and to 
minimise reversible inhibition. If the inhibitor is also a potential reversible inhibitor, more 
than 20-fold dilution is needed (Grimm et al., 2009). The concentration of the probe substrate 
should approach saturation (≥ 4-fold Km) (Grimm et al., 2009). In addition, the incubation 
time should be clearly shorter than the preincubation time, to minimise the possibility of 
reversible or further irreversible inhibition. 
 
From the data obtained, several different plots can be drawn and kinetic constants calculated 
(Ghanbari et al., 2006). The basic graphical plots for mechanism-based inhibition are those 
presenting the natural logarithm of the remaining enzyme activity against the preincubation 
time. Separate plots for different inhibitor concentrations are drawn. The apparent rates of 
inactivation (kobs) can be estimated graphically from the slopes (Figure 6A). 
 
A double reciprocal plot of the obtained kobs against the inhibitor concentration can be used 
for the calculation of the kinact and KI (Figure 6B). Alternatively, a Kitz-Wilson plot of the 
half-life of the inactivation against the inhibitor concentration can be used (Alexander et al., 
1963; Kitz and Wilson, 1963). 
 
The constants kinact and KI have been shown not to correlate between each other, indicating 
that both time of exposure and inhibitor concentration are independent determinants of 
enzyme inactivation (Zhou et al., 2005b). The relationships between kobs, kinact and KI are 
shown in Figure 6C. 
 
The partition ratio, an indicator of the efficiency of a mechanism-based inhibitor, can be 
estimated from a plot with the remaining enzyme activity against the molar ratio of the 
inhibitor to the enzyme. An estimation of the partition ratio (r) can be calculated from the 
point of the intercept (number of turnovers, including the inactivation, in the case of 1:1 






Figure 6. A) Plots of percentage of the remaining enzyme activity (ln) versus preincubation time. B) 
Double-reciprocal plot of kobs versus inhibitor concentration. C) The relationships between kobs, kinact 
and KI. D) Plot for the estimation of the partition ratio (r). 
 
 
The constants presented above serve as parameters of inactivator efficiency. In addition, the 
ratio of kinact/KI may serve as an additional indicator of it (Polasek et al., 2004). 
 
Inactivation kinetic constants of some drugs which are mechanism-based inhibitors of CYP 

















Table 5. Inactivation kinetic constants of mechanism-based inhibitors. 
Inhibited enzyme  
Inhibitor drug 
(probe drug) kinact (1/min) KI (µM) 
Partition 
ratio Reference 
CYP1A2 Isoniazid 0.11 285  (Wen et al., 2002b) 
Rofecoxib 0.07 4.8  (Karjalainen et al., 2006) 
Zileuton 0.035 117  (Lu et al., 2003) 
CYP2A6 Isoniazid 0.13 173  (Wen et al., 2002b) 
CYP2B6 Clopidogrel 1.5 1.1  (Richter et al., 2004) 
Ticlopidine 0.8 0.8  (Richter et al., 2004) 
CYP2C8 Gemfibrozil 1-O-
β-glucuronide 
0.21 20  (Ogilvie et al., 2006) 
Gemfibrozil 1-O-
β-glucuronide 
0.072 29 53 (Baer et al., 2009) 
CYP2C19 Clopidogrel 0.35 0.5  (Richter et al., 2004) 
Clopidogrel 0.056 14.3  (Nishiya et al., 2009) 
Isoniazid 0.09 112  (Wen et al., 2002b) 
Ticlopidine 0.192 87 26 (Ha-Duong et al., 2001) 
Ticlopidine 0.5 0.2  (Richter et al., 2004) 
Ticlopidine 0.097 4.3  (Obach et al., 2007) 
Ticlopidine 0.074 3.32  (Nishiya et al., 2009) 
Omeprazole 0.046 9.1  (Paris et al., 2008) 
CYP2D6 Paroxetine 0.17 0.315*  (Venkatakrishnan and 
Obach, 2005) 
CYP3A4 Diltiazem 0.17 2.2  (Jones et al., 1999) 
Diltiazem 0.07 3.3 19.7 (Rowland Yeo and Yeo, 
2001) 
Clarithromycin 0.072 5.49  (Mayhew et al., 2000) 
Delavirdine 0.59 21.6 41 (Voorman et al., 1998) 
Diltiazem 0.027 0.77  (Mayhew et al., 2000) 
Erythromycin 
(midazolam) 
0.036 10  (Obach et al., 2007) 
Erythromycin 
(testosterone) 
0.039 9.8  (Obach et al., 2007) 
Ethinylestradiol   120 (Guengerich, 1988) 
Ethinylestradiol 0.04 18 50 (Lin et al., 2002) 
Fluoxetine 0.017 5.26  (Mayhew et al., 2000) 
Gestodene 0.4 46 9 (Guengerich, 1990) 
Imatinib 0.072 14.3  (Filppula et al., 2011a) 
Isoniazid 0.08 228  (Wen et al., 2002b) 
Lapatinib 0.020 1.71 50.9 (Teng et al., 2010) 




0.45 0.38  (Obach et al., 2007) 
Ritonavir 
(testosterone) 
0.28 0.18  (Obach et al., 2007) 




0.043 1.8  (Obach et al., 2007) 
Verapamil 
(testosterone) 
0.043 1.7  (Obach et al., 2007) 
Zolpidem 0.094 122  (Polasek et al., 2010) 
CYP3A5 Fluticasone 0.027 16 3 (Murai et al., 2010) 





5.3. Enzyme degradation rate 
 
The enzyme synthesis rate is generally assumed to be a zero-order process (occurs at the same 
rate regardless of the concentration), whereas the rate of degradation is a first-order process 
(occurs at a rate dependent on the concentration) (Yang et al., 2008). The first-order rate 
constant characterising the in vivo turnover / degradation of the CYP enzyme (kdeg) is 
essential for the IVIVE of interactions caused by mechanism-based inhibition. The enzyme 
turnover half-life can be calculated from the first-order degradation rate by the equation half-
life (t1/2) = ln2/kdeg. The enzyme degradation rate is a physiological value depending on the 
enzyme, individual and species concerned. As the half-lives of, e.g., rat CYPs are shorter than 
their human counterparts, their use in IVIVE can under-predict the risk and consequences of 
mechanism-based inhibition. Therefore, it would be best to use human CYP in vivo 
degradation rates for the IVIVE of human drug interactions. The human CYP in vivo kdeg 
values cannot be measured directly. Therefore, several approaches have been used to obtain 
reliable estimates of them. 
 
In vitro methods for estimating the turnover half-life of human CYPs have been used 
extensively. Direct measurement of the turnover half-life, e.g., by the pulse-chase method, or 
rates of loss of the apoprotein contents and enzymatic activity from liver slices or primary 
cultured hepatocytes have been used, but they do not necessarily provide reliable results due 
to the loss of in vivo conditions. In addition, in vitro induction in human hepatocytes can be 
used for the estimations (Yang et al., 2008). 
 
Estimates of human in vivo CYP enzyme half-lives can also be achieved by indirect human in 
vivo methods. One method is to analyse the reversal of increased enzyme activity after 
induction. The recovery of the enzyme activity to basal level is a function of enzyme turnover 
and any persistence of the inductive effect of the inducer. Therefore, in this method, the 
inducer should preferably have a short half-life. In addition, the probe substrate used for 
assessing the enzyme activity should have a short half-life and be extremely specific for the 
enzyme concerned. In the method utilising mechanism-based inhibition, the degradation half-
life is estimated based on the recovery of the enzyme activity to basal level after inactivation. 
The inhibitor should have a much shorter half-life compared to the enzyme concerned to yield 
accurate predictions (Yang et al., 2008). In addition, pharmacokinetic modelling of CYP 
autoinduction can be used in the estimation of enzyme turnover (Yang et al., 2008). 
 
The turnover half-life for intestinal CYPs can be estimated in vivo by inhibitors in doses that 
inactivate only the intestinal CYP and leave the hepatic CYP unchanged. E.g., the intestinal 
CYP3A4 turnover half-life has been estimated at 23 h by using single doses of grapefruit 
juice as the inhibitor (Greenblatt et al., 2003). However, as the process for enterocyte 
maturation is probably faster than enzyme turnover, intestinal CYP half-lives are likely to be 
determined by cell rather than enzyme turnover (Yang et al., 2008). 
 
Human CYP enzymes can be divided into two groups based on their estimated degradation 
rates, most of which have been yielded by in vitro methods. CYP2C9, CYP2D6, CYP3A4 and 
CYP4A11 can be considered relatively stable (half-lives between 70 and 104 h), compared to 
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CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1 and CYP3A5, which were 
considered relatively unstable (half-lives between 23 and 36 h) (Renwick et al., 2000). 
 
The sensitivity of the predicted drug-drug interaction to the enzyme degradation rate used has 
been studied at least for CYP2D6 and CYP3A4. Not surprisingly, the predictions were most 
sensitive to different kdeg values when the fm values of the substrate were the largest 
(Venkatakrishnan and Obach, 2005; Galetin and Houston, 2006). 
5.4. In vitro – in vivo extrapolation 
 
The prediction of the clinical importance of mechanism-based inactivation based on in vitro 
studies is more complicated than that of reversible inhibition. In addition to the [I]/KI ratio, 
the kinact/kdeg ratio is an independent factor in the inhibition potential. Therefore, even if the 
[I]/KI ratio is very small, the clinical interaction can be relevant in case of very rapid 
inactivation making the kinact/kdeg ratio sufficiently large (Venkatakrishnan and Obach, 2007). 
 
The following equation can be used for the extrapolation of the in vivo potency of a 
mechanism-based inhibitor: 
 








If the obtained index is << 1, a weak inhibition can be expected, with a victim drug AUC fold 
increase of ≤ 2. The opposite applies to moderate and potent inhibition (Zhou and Zhou, 
2009). 
 
The clinical impact of mechanism-based inhibition on CYP-mediated clearance can be 
predicted from in vitro inactivation data using the following mathematical model, which takes 
the importance of the inactivated enzyme to the substrate metabolism into account (Mayhew 































If the inhibitor concentration ([I]) is below KI, a simplified version of the equation presented 































These mathematical models are based on a number of simplifying assumptions: 1) the 
substrate drug is well absorbed and the inhibitor has no effect on its absorption, 2) the 
substrate exhibits linear pharmacokinetics and is metabolised by the liver only, 3) the hepatic 
clearance of the substrate can be described by the well stirred model and 4) the degradation 
rate of the enzyme is a first order process and the inhibitor has no effect on it (Lu et al., 2003). 
 
The inactivation of the intestinal enzyme is relevant for at least predictions of CYP3A4 

























































where Fg is the fraction of the dose of the affected drug that passes through the intestine 
unchanged after oral administration in the control state, [I]g is the concentration of the 
inhibitor in the intestine, kdeg,gut is the in vivo degradation rate of the enzyme in the intestine 
and kdeg,hep is the in vivo degradation rate of the enzyme in the liver. 
 
The selection of the inhibitor concentration to be used in the clinical drug-drug interaction 
predictions, as discussed already for IVIVE in general, is important also for mechanism-based 
inhibitors. For mechanism-based inhibitors, the use of Cmax in the extrapolations has yielded 
the most accurate predictions of the interaction potential (Obach et al., 2007; Obach, 2009; 
Sato et al., 2010). In addition to the issues related to concentration selection, mispredictions 
may arise due to plasma protein binding, atypical substrate pharmacokinetics, the existence of 
inhibitory metabolites, the partitioning from plasma to liver, the rate-limiting transport of the 
substrate and the inhibitor into the hepatocytes, the intestinal active efflux of the substrate and 
inhibitor as well as the extrahepatic metabolism of both players (Zhou et al., 2005b). 
 
Mechanism-based inhibition can be modelled by PBPK modelling techniques. The 
sorivudine-5-fluorouracil interaction causing fatal outcomes in Japan could be quantitatively 
predicted later with a PBPK model. Similarly, the interaction between mechanism-based 
CYP3A4 inhibitor erythromycin and CYP3A4 substrate triazolam was predicted by PBPK 
model (Kanamitsu et al., 2000a; Kanamitsu et al., 2000c; Ito et al., 2003). The accuracy of the 
predictions of mechanism-based inhibition by static models and PBPK modelling has been 
compared. Some results have indicated that static models would provide more accurate 








5.5. The role of in vivo animal studies 
 
Due to the limitations of in vitro and in silico methods, in vivo animal studies (usually in mice 
and rats) have also been used in the assessment of mechanism-based inhibition. Interspecies 
variation in many aspects, e.g., in the CYP amino acid sequence, substrate specificity and 
catalytic activity, however, can cause difficulty in extrapolating animal data to humans, but it 
is particularly challenging in the case of mechanism-based inhibition (Lin, 1995; Zhou et al., 
2005b; Sekiguchi et al., 2008; Zhang et al., 2010). Monkeys have been proposed recently as a 
suitable model animal to predict drug-drug interactions caused by the mechanism-based 
inhibition of CYP3A (Ogasawara et al., 2009). An approach of combining data from in vivo 
rat studies and in vitro studies with human enzymes could also be useful to evaluate risks in 
clinical studies (Sekiguchi et al., 2008). Further, at least for CYP3A inactivation, CYP 
enzyme humanised mice have been proposed to be used for evaluating mechanism-based 
inhibition (Aueviriyavit et al., 2010). 
 
In spite of rigorous in vitro methods, in vivo animal studies and advanced IVIVE techniques, 
clinical drug-drug interaction studies in humans may be needed anyway for the evaluation of 
the mechanism-based inhibition potential of new chemical entities. Probe substrates for 
studying the activity of major CYPs involved in drug metabolism in humans have been 
recommended by the Food and Drug Administration of United States (FDA, 2006). 
 
6. Effects of time and dose on mechanism-based inhibition 
 
Mechanism-based inhibition is both a time- and concentration-dependent phenomenon. Its 
time and dose relationships have been studied extensively in vitro. The time-dependency of 
inhibition is required to show that an agent is a mechanism-based inhibitor. Concentration-
dependency is used to determine the in vitro kinetic constants. However, data concerning the 
time and dose relationships of mechanism-based inhibition in vivo in humans is sparse. 
6.1. Effects of time on mechanism-based inhibition 
 
Onset of the inhibitory effect. There are only a few publications available regarding the 
onset of mechanism-based inhibition. In vitro and in vivo studies examining the onset of the 
inhibitory effect concern mainly the inactivation of CYP3A4 by grapefruit constituents. The 
inhibitory effect of grapefruit juice has been shown to have reached its maximum already 
after the first dose (on day 1), when reflected as changes in felodipine pharmacokinetics on 
day 1 and day 14, compared to control (Lundahl et al., 1998). The onset of the mechanism-
based inhibition caused by grapefruit juice furanocoumarins bergamottin and 6’,7’-
dihydroxybergamottin has been compared in vitro using CYP3A4-expressing human 
colorectal adenocarcinoma derived Caco-2 cells and midazolam and testosterone as probe 
drugs. The inactivation of CYP3A4 was shown to occur more rapidly by 6’,7’-
dihydroxybergamottin than by bergamottin. 6’,7’-dihydroxybergamottin inhibited the 
CYP3A4-mediated metabolism of the probe drugs > 85% already in 30 minutes, whereas the 
CYP3A4 inhibition by bergamottin reached a level of ≥ 70% after 3 h (Paine et al., 2005). 
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The onset of inhibitory effects by ritonavir has recently been studied. The inhibition, 
measured as a decrease in midazolam clearance, developed to its maximum in 48 h after 
starting ritonavir 300 mg twice daily (Katzenmeier et al., 2011). In addition, physiologically-
based pharmacokinetic modelling has been used to predict the onset of mechanism-based 
inactivation of CYP enzymes. MDMA (ecstasy) was estimated to inactivate CYP2D6 already 
in 1 h (Yang et al., 2006). 
 
Recovery from the inhibitory effect. One characteristic of mechanism-based inhibition is 
that, in contrast to reversible inhibition, it persists even after the removal of the inhibitor. The 
inhibition is reversed in vivo by de novo synthesis of the protein, and the rate of the recovery 
to basal state is determined by the first-order degradation rate (kdeg) / the half-life (t1/2) of the 
inhibited enzyme. The methods for estimating these have been described in section 5.3. 
 
Examples of published data from in vivo studies regarding the half-lives / recovery time of 
clinically relevant CYP enzymes are provided in Table 6. 
 
 
Table 6. Examples of clinical studies with data on CYP enzyme half-lives / enzyme recovery after 
mechanism-based inhibition or induction. 
CYP 
enzyme 
Inhibitor Inducer Probe for enzyme 
activity 
Results  Reference(s) 
CYP1A2 - Smoking Caffeine t½ = 39 h (Faber and Fuhr, 2004) 
CYP2C8 Gemfibrozil - Repaglinide Inhibitory effect 
lasts at least 12 h 




- Dextrometorphan t½ = 70 h, 
corrected with 
paroxetine half-
life and using 
PBPK modelling 
to 51 h 





- Dextrometorphan t½ = 47 h, 
recovery takes 10 
days 
(O'Mathuna et al., 
2008) 
CYP2E1 - Alcohol Chlorzoxazone t½ ≈ 60 h (Lucas et al., 1995) 
 Disulfiram - Chlorzoxazone t½ = 50 h (Emery et al., 1999) 
CYP3A4 Grapefruit juice - Felodipine Inhibitory effect 
lasts at least 24 h; 
t½ = 8 h 
(Lundahl et al., 1995; 
Takanaga et al., 2000a) 
 Grapefruit juice - Nisoldipine Recovery takes > 
3 days 
(Takanaga et al., 
2000b) 
 Grapefruit juice - Simvastatin Recovery takes 3-
7 days 
(Lilja et al., 2000b) 
 Grapefruit juice - Midazolam t½ = 23 h 
(intestinal 
CYP3A4) 
(Greenblatt et al., 2003) 





- Triazolam Recovery takes 3 
days 
(Culm-Merdek et al., 
2006) 
 Ritonavir - Midazolam Inhibitory effect 
lasts at least 3 
days 




6.2. Effects of dose on mechanism-based inhibition 
 
It is generally accepted that the in vivo inhibitory effect of mechanism-based inhibitors is 
based on the kinact, KI, kdeg and the dose (concentration of the inhibitor at the enzyme active 
site). The dose-dependency of inhibition of drug metabolism has been reported for some 
reversible and irreversible inhibitors. However, human in vivo studies on the effect of the dose 
on mechanism-based inhibition are quite sparse (Levy et al., 2003). 
 
Examples of in vivo human studies providing results on the dose-dependency of the 
interactions caused by agents known to be mechanism-based inhibitors of CYP enzymes are 
provided in Table 7. Studies concerning weak mechanism-based potential are excluded. It 
should be noted that the compounds may also have other mechanisms than mechanism-based 
inhibition leading to changes in the substrate concentrations. E.g., the substrate drug may be 
metabolised by several enzymes. The other mechanisms leading to the changes in substrate 
concentrations may include various factors such as additional reversible inhibition or 
induction of the same enzyme; inhibition and induction of other enzymes; and inhibition and 
induction of transporter proteins contributing to the substrate drug’s disposition. Therefore, 
these results concerning dose-dependency may not be related to mechanism-based inhibition, 
but reflect the dose-dependency of the total effect of the perpetrator on the clearance of the 
substrate drug. In some of the studies no dose-dependency could be shown. This may be due 
to a small number of doses being studied. The inhibition may have been large already at the 
small inhibitor doses studied, and therefore no significant further increase in the inhibition 
could be obtained with large doses. In these dose-dependency studies (Table 7), a use of 
PBPK models was not reported. 
 
Studies designed for assessing the dose-dependency of mechanism-based inhibitors have 
provided also other interesting results. Bailey et al. tried to study the dose-/concentration-
dependency of mechanism-based inhibition in vitro and in vivo. The concentrations of 
bergamottin in grapefruit and lime juice were made equal by diluting lime juice with water to 
¼ strength of the original. The CYP3A4 inhibitory effects of the juices were compared. 
Grapefruit juice was shown to inhibit CYP3A4 metabolism more than lime juice, indicating 
that bergamottin is not likely to be the primary substance in grapefruit juice causing 
mechanism-based CYP3A4 inactivation (Bailey et al., 2003). Later, the difference in the 
inactivation has been detected to be due to 6’,7’-dihydroxybergamottin, which is present in 
grapefruit juice and absent in lime juice (Paine et al., 2005). 
 
Veronese et al. (2003) have studied the inhibitory potency of two doses of grapefruit juice on 
CYP3A4 and they have also attempted to determine the major issue of this CYP3A4-
inhibition. In that study, double-strength grapefruit juice or water was administered once daily 
for 2 days, and then, 90, 60 and 30 min before the probe drug (midazolam) on day 3. The 
study included an additional part in which single doses of normal-strength and double-
strength grapefruit juice or water were administered. Double-strength grapefruit juice in 
multiple doses was shown to increase the AUC, Cmax and t1/2 of midazolam, and decrease the 
amount of exhaled 14CO2 in the erythromycin breath test compared to the control (water) 
phase, which was considered to reflect the inhibition of both intestinal and hepatic CYP3A4.  
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Table 7. Examples of in vivo human studies providing data concerning the dose-dependency of 
mechanism-based inhibitors. 
Inhibitor Inhibitor dosing 
scheme 
Substrate(s) Results relating to inhibitor dose Reference 
Cimetidine 1000 or 1600 mg 
daily for 4 days. 
Tolbutamide, 
antipyrine 
1000 mg had no significant effect 
on tolbutamide or antipyrine 
elimination; 1600 mg impaired the 
elimination of both substrates. 
(Back et al., 1988) 
Cimetidine 800 mg or 1200 
mg daily for 15 
days. 
Warfarin No dose effect shown. (Sax et al., 1987) 
Diltiazem 30 or 90 mg three 
times a day for 3 
days. 
Nifedipine The mean AUC of nifedipine 
increased with both diltiazem 
doses, the increase was larger with 
a 90 mg dose (3.1) than with a 30 
mg dose (2.2) (P < 0.05). 
(Tateishi et al., 
1989) 
Diltiazem 10, 20, 30, 60, 120 
or 180 mg daily 
for ≥ 2 weeks. 
Tacrolimus Dose-dependent increases in 
tacrolimus AUC. 
(Jones and Morris, 
2002) 
Disulfiram 250 mg or 500 mg 
daily for 4 or 5 
days. 
Caffeine No dose effect shown. (Beach et al., 
1986) 
Disulfiram 250 or 500 mg 
daily for 8 days. 
Theophylline Decrease in theophylline clearance 
with 500 mg disulfiram was larger 
(33%) than with 250 mg (21%) (P 
< 0.01). 
(Loi et al., 1989) 
Grapefruit 
juice 
200 ml of normal-
strength juice 
once, 200 ml of 
double-strength 
juice once or 3 
times daily for 2 
days. 
Triazolam Triazolam concentrations were 
increased more with double-
strength grapefruit juice in the 
multiple dosing scheme (AUC 2.4-
fold) than in the single dosing 
schemes with double-strength 
(AUC 1.5-fold) and single-strength 
(AUC 1.5-fold) juice. 
(Lilja et al., 
2000a) 
Paroxetine 10 mg twice daily 
for 7 days, 20 mg 
twice daily during 
the consecutive 7 
days. 
Nortriptyline Nortriptyline concentrations were 
increased more after 20 mg doses 
(5-6-fold) than after 10 mg doses 
(3-fold) of paroxetine (p ≤ 0.01). 
(Laine et al., 
2001) 
Ritonavir 100 or 300 mg 
twice daily for 7 or 
14 days. 
Amprenavir No other dose effect of ritonavir 
shown than adverse events more 
frequent with 300 mg dose. 
(Sadler et al., 
2001) 
Ritonavir 200, 300 or 400 
mg twice daily for 
14 days. 
Saquinavir 400 mg ritonavir increased 
saquinavir concentrations 
marginally more than lower doses. 
(Buss et al., 2001) 
Ritonavir 200, 300 or 400 
mg twice daily for 
15 days. 
Indinavir No dose effect shown. (Hsu et al., 1998) 
Ritonavir 100 or 200 mg 
daily for 14 days. 
Nelfinavir No dose effect shown. (Kurowski et al., 
2002) 
Verapamil 80 mg three times 
daily for 3 days, 
120 mg three times 
daily for 3 
consecutive days. 






In contrast, a single dose of grapefruit juice (either normal or double-strength), increased only 
the AUC and Cmax of midazolam, with only minimal effects on midazolam t1/2 or the 
erythromycin breath test, indicating a preferential inhibition of intestinal CYP3A4. In this 
study, the effects of single doses of normal and double-strength grapefruit juice on midazolam 
pharmacokinetics or the erythromycin breath test did not differ significantly from each other 
(Veronese et al., 2003). 
 
A proper assessment of human in vivo dose-dependency of inhibitory potency requires the 
incorporation of data concerning the dose-proportionality of the inhibitor. The assessment of 
the dose-proportionality is also needed for other purposes than the assessment of the 
inhibitory potency of the compound, and is currently a standardised part of the drug 
development process. Dose-proportionality assessments are recommended to be done by 
cross-over methods and power-model statistical approaches, at least if the number of subjects 
in the pharmacokinetic study is small (Sheng et al., 2010). 
 
7. Management and utilisation of mechanism-based inhibition 
 
The finding that a compound is a mechanism-based inhibitor does not necessarily mean that it 
cannot be used as a therapeutic agent. In fact, many widely used drugs are mechanism-based 
inhibitors (Jones and Hall, 2002) (Table 5). However, caution should be exercised, when 
many of these drugs are used clinically. Tools for the management of mechanism-based 
inhibition include early identification of the drugs behaving as irreversible inhibitors, rational 
use of such drugs, therapeutic drug monitoring and prediction of risks for potential drug-drug 
interactions (Zhou et al., 2005a). A rational use of mechanism-based inhibitors can be 
achieved, e.g., by selecting the patients’ concomitant drugs carefully, adjusting the dose of the 
inhibitor or substrate drug and by discontinuing treatment in case of toxic interactions. One 
additional tool is the development of “hard drugs” which are non-metabolisable and therefore 
avoid mechanism-based inhibition (Zhou, 2008). 
 
Since the first description of the phenomenon of mechanism-based inhibition of enzymes it 
has been widely used in enzymology and clinical drug therapy (Osawa and Pohl, 1989; Lin 
and Lu, 1998). For example the inactivation of xanthine oxidase by allopurinol has been used 
in the treatment of gout (Massey et al., 1970; Silverman, 1988). Other clinical examples 
include ritonavir, which is frequently used with other protease inhibitors (e.g., saquinavir, 
lopinavir, indinavir and amprenavir) in the treatment of human immunodeficiency virus 
infection as it has been shown to enhance their oral bioavailability and to increase their 
concentrations in plasma (Kurowski et al., 2002). This effect is at least partly due to the 








8. Cytochrome P450 2C8 
 
The cytochrome P450 2C8 enzyme (CYP2C8) was purified from the human liver in the 
1980’s (Lasker et al., 1987). It is a key member of the CYP2C family and accounts for 
approximately 6-7% of the total hepatic CYP content. The role of CYP2C8 in drug 
metabolism and especially in drug-drug interactions and pharmacogenomics has been 
recognised only recently (Totah and Rettie, 2005). It has been estimated that CYP2C8 
metabolises 5-8% of drugs which are cleared by phase I reactions (Lai et al., 2009). Examples 
of endogenous and exogenous substrates of CYP2C8 are shown in Table 8. 
 
 
Table 8. Examples of substrates, inhibitors and inducers of CYP2C8. 
Substrates  Reference Inhibitors  Reference 
All-trans-retinoic acid (Marill et al., 2000) Amiodarone (Polasek et al., 2004) 
Amiodarone (Ohyama et al., 2000) Clotrimazole (Ong et al., 2000) 
Amodiaquine (Li et al., 2002) Fluoxetine (Polasek et al., 2004) 
Arachidonic acid (Rifkind et al., 1995) Gemfibrozil (Wang et al., 2002) 
Chloroquine (Kim et al., 2003) Gemfibrozil 1-O-β 
glucuronide 
(Ogilvie et al., 2006) 
Cerivastatin (Wang et al., 2002) Isoniazid (Polasek et al., 2004) 
Fluvastatin (Prueksaritanont et al., 1999) Ketoconazole (Ong et al., 2000) 
Ibuprofen (Hamman et al., 1997) Montelukast (Walsky et al., 2005) 
Loperamide (Kim et al., 2004) Nortriptyline (Polasek et al., 2004) 
Montelukast (Karonen et al., 2010; 
Filppula et al., 2011b)  
Quercetin (Bun et al., 2003) 
Morphine (Projean et al., 2003) Trimethoprim (Wen et al., 2002a; Hruska et 
al., 2005) 
Paclitaxel (Rahman et al., 1994) Verapamil (Polasek et al., 2004) 
Pioglitazone (Jaakkola et al., 2006) Inducers Reference 
Repaglinide (Bidstrup et al., 2003) Dexamethasone (Gerbal-Chaloin et al., 2001) 
Rosiglitazone (Baldwin et al., 1999) Phenobarbital (Gerbal-Chaloin et al., 2001) 
Troglitazone (Yamazaki et al., 1999) Rifampicin (Gerbal-Chaloin et al., 2001) 
  
 
The size of CYP2C8 is approximately 2.7 Å and its molecular mass is 53.5 kDa. Its substrate 
binding cavity is relatively large (1438 Å3) compared to many other human CYPs. Due to its 
large substrate binding cavity CYP2C8 can accommodate several large substrates and 
inhibitors, such as paclitaxel and montelukast (Schoch et al., 2008). As CYP3A4 also has a 
large substrate binding cavity (1386 Å3), many substrates of CYP2C8 are also metabolised by 
CYP3A4 (Lai et al., 2009). CYP2C8 exists as dimers in natural membranes (Schoch et al., 
2004), and this has been proposed to have functional significance (Hu et al., 2010).  
 
CYP2C8 is principally expressed in the liver. However, the messenger ribonucleic acid 
(mRNA) of the CYP2C8 and/or CYP2C8 protein have been detected in many extrahepatic 
tissues, e.g., the duodenum, kidney, adrenal gland, heart, lung, brain, mammary gland, uterus 
and ovary (Klose et al., 1999; Läpple et al., 2003; Enayetallah et al., 2004; Delozier et al., 
2007; Michaud et al., 2010). 
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The CYP2C8 gene is located in the chromosome 10q24 near other CYP2C genes in the 
following order from centromere to telomere: Cen-2C18-2C19-2C9-2C8-Tel (Gray et al., 
1995). The CYP2C8 gene spanning 31 kb and containing 9 exons is the smallest gene in the 
CYP2C family (Klose et al., 1999). At least nuclear receptors glucocorticoid receptor (GR), 
pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are considered to 
participate in the regulation of CYP2C8 (Gerbal-Chaloin et al., 2001; Lai et al., 2009). Since 
the first report of CYP2C8 gene polymorphism in 2001 (Dai et al., 2001), at least 15 variants 
of the CYP2C8 gene have been identified to date (http://www.cypalleles.ki.se). At least some 
of the genetic polymorphisms in CYP2C8 have functional significance (Daily and Aquilante, 
2009). The wild type of the CYP2C8 gene is named as CYP2C8*1. CYP2C8*2, encoding a 
CYP2C8 protein with decreased paclitaxel hydroxylation activity in vitro, is expressed in 
black populations with an allele frequency of 18%, but is very rare in white subjects (allele 
frequency < 1% in Caucasians) (Dai et al., 2001). CYP2C8*3, instead, is frequently expressed 
in white subjects (allele frequency 15%) (Bahadur et al., 2002). The functional activity level 
of the CYP2C8.3 protein encoded by CYP2C8*3 is currently ambiguous. CYP2C8*3 has been 
associated with decreased arachidonic acid and paclitaxel metabolism in vitro and for 
paclitaxel also in vivo (Dai et al., 2001; Bahadur et al., 2002; Lundblad et al., 2005; 
Bergmann et al., 2011). In contrast, amiodarone metabolism was not shown less effective 
with CYP2C8.3 than with CYP2C8.1 (Soyama et al., 2002). Furthermore, in in vivo studies, 
CYP2C8*3 has been associated with increased metabolic activity, e.g., towards repaglinide, 
rosiglitazone and pioglitazone (Niemi et al., 2003c; Kirchheiner et al., 2006; Tornio et al., 
2008b). Several explanations for this in vitro - in vivo discrepancy have been proposed, such 
as compensatory upregulation of other CYP enzymes in vivo in subjects carrying CYP2C8*3 
(Niemi et al., 2003c). Recently, a new theory of substrate dependent interactions of 
CYP2C8.3 and cytochrome P450 reductase and cytochrome b5 was proposed (Kaspera et al., 
2011). The allele frequency of CYP2C8*4 encoding a protein with conflicting data concerning 
enzymatic activity, is 7.5% in Caucasians (Bahadur et al., 2002). It was also recently 
suggested that in addition to different metabolic activities, the genetic variants of CYP2C8 
may have altered drug inhibitory susceptibilities compared to CYP2C8.1 (Gao et al., 2010). 
Genetic variance in CYP2C8 has been observed to be associated with the risk of myocardial 
infarction (Yasar et al., 2003). This is considered to be related to the metabolism of 
arachidonic acid to epoxyeicosatrienoic acids, which are supposed to have a cardiovascular 
protective role (Rodenburg et al., 2010). 
 
In addition to genetic issues, CYP2C8 activity can vary due to various factors such as 
concomitantly used drugs (Table 8). CYP2C8 activity is determined in vitro by using 
paclitaxel 6α-hydroxylation and amodiaquine N-deethylation assays. Rosiglitazone, retinoic 
acid, fluvastatin and torsemide have also been suggested as in vitro probes for CYP2C8 
activity (Melet et al., 2004). For in vivo studies, repaglinide, rosiglitazone, pioglitazone, 
cerivastatin and most recently montelukast have been recommended as probe substrates 
(FDA, 2006; Lai et al., 2009; Karonen et al., 2011; VandenBrink et al., 2011). Also 
pharmacologically inactive enantiomer of ibuprofen, R-ibuprofen has been proposed to be 
used as an in vivo probe for CYP2C8 activity (Lai et al., 2009). However, it seems to be very 
insensitive to the inhibition of CYP2C8 (Tornio et al., 2007). 
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9. Gemfibrozil and gemfibrozil 1-O-β-glucuronide 
 
Gemfibrozil is a fibric acid derivative developed for the treatment of dyslipidaemia. It was 
discovered in the 1960’s and the first clinical study in healthy volunteers was carried out in 
1971 (Smith, 1976). Gemfibrozil was well-tolerated in early studies and it reduced 
triglyceride levels and increased high-density lipoprotein levels in the subjects. The 
pharmacological actions of gemfibrozil are mediated mainly through peroxisome proliferator 
activated receptor alpha (PPARα) stimulation, but its consequences are not completely 
understood. They are considered to involve at least a stimulation of free fatty acid oxidation, 
an increase in lipoprotein lipase activity and a decrease in the synthesis of apolipoprotein C-
III. The basic characteristics of gemfibrozil are shown in Table 9. 
 
 
Table 9. Characteristics of gemfibrozil (Okerholm et al., 1976; Todd and Ward, 1988; Miller and 
Spence, 1998; Bersot, 2010). 
Chemical structure 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoicacid, C15H22O3 
Molecular weight 250.3 
Usual daily dosage 600 mg twice or 900 mg once daily 
Oral bioavailability (F) Almost 100% 
t1/2 1.5 h 
Plasma protein binding > 99% (mainly to albumin) 
Volume of distribution (Vd) 9-13 l 
Metabolism Glucuronidation, phase I reactions 
Route of excretion Renal (66%), biliary (6%) 
 
 
Gemfibrozil was first marketed in the United States in 1982. Since then, marketing 
authorisation for gemfibrozil has been granted in many other countries. Based on the results 
from the Helsinki Heart Study in 1987 gemfibrozil was shown to reduce cardiac endpoint 
events in patients with primary hyperlipidaemia by 34% compared to placebo. In addition, 
mortality due to coronary disease decreased by 26%, but there were no differences in the total 
mortality between the gemfibrozil and placebo groups (Frick et al., 1987). In a secondary 
prevention study, similarly, gemfibrozil decreased both fatal and nonfatal coronary events by 
22% (Rubins and Robins, 2000). Based on these promising clinical studies gemfibrozil was 
considered as well-tolerated in clinical use (Athyros et al., 1997; Murdock et al., 1999). 
 
In the 1990’s reports of increased incidence of rhabdomyolysis in patients treated 
concomitantly with gemfibrozil and 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) 
reductase inhibitors (statins) were published (Furberg and Pitt, 2001). About one third of the 
patients treated with cerivastatin, who developed fatal rhabdomyolysis, had used gemfibrozil 
concomitantly. Since both gemfibrozil and statins can cause myopathy, a pharmacodynamic 
interaction was suspected. However, later the plasma concentrations of cerivastatin were 
shown to be increased by more than 5-fold by gemfibrozil in conjuction with a large reduction 
in the concentrations of the CYP2C8-dependent major metabolite of cerivastatin (Backman et 
al., 2002). Although the clinical use of gemfibrozil has decreased, it has a role in the 
management of hyperlipidaemia in certain individuals such as in patients with isolated 
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hypertriglyceridaemia, diabetes mellitus or metabolic syndrome (Barter and Rye, 2008; 
Loomba and Arora, 2010) and in the case of intolerance of statin treatment. In addition, the 
drug-drug interaction potential of gemfibrozil can be utilised both in in vitro and in vivo 
studies during drug development. It is of interest that gemfibrozil is currently a recommended 
model inhibitor of CYP2C8 for in vitro and in vivo studies by regulatory authorities (FDA, 














































Figure 7. Gemfibrozil 1-O-β-glucuronide formation and metabolism (Ogilvie et al., 2006). 
 
 
9.1. In vitro and in vivo effects of gemfibrozil and gemfibrozil 1-O-β-glucuronide 
 
Gemfibrozil is glucuronidated to 1-O-β-glucuronide in the hepatocytes mainly by the uridine-
5’-diphosphoglucuronosyltransferase (UGT) 2B7 enzyme (Mano et al., 2007) (Figure 7). This 
process converts gemfibrozil to a potent mechanism-based inhibitor of CYP2C8 (Ogilvie et 
al., 2006). CYP2C8 catalyses benzylic oxidation of the glucuronide, which leads to haem 
alkylation and inactivation of CYP2C8 (Baer et al., 2009; Jenkins et al., 2011). Inhibition of 
CYP2C8 by gemfibrozil 1-O-β-glucuronide was estimated to lead to kinact value of 0.21 min-1 
in human liver microsomes (HLM). KI values were determined to be 20 and 52 µM using 
microsomal concentrations of 0.1 and 1.0 mg/ml, respectively (Ogilvie et al., 2006). 
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Table 10. Reported in vitro inhibitory effects of gemfibrozil and gemfibrozil 1-O-β-glucuronide on 
some enzymes and transporters. 
Enzyme/ 
transporter 
Effects of gemfibrozil Effects of gemfibrozil 1-O-β-glucuronide 
CYP1A2 IC50 99 µM 
Ki 82 µM  
(Ogilvie et al., 2006) 
(Wen et al., 2001) 
NS at 300 µM  (Ogilvie et al., 2006) 
CYP2A6 NS at 250 µM  (Wen et al., 2001) -  
CYP2B6 NS at 300 µM  (Ogilvie et al., 2006) NS at 300 µM  (Ogilvie et al., 2006) 
CYP2C8 IC50 120 µM 
IC50 28 µM 
Ki 55.4 µM 
 
(Ogilvie et al., 2006) 
(Shitara et al., 2004) 
(Fujino et al., 2003) 
 
IC50 4.07 µM 
IC50 decreased from 
24 to 1.8 µM after a 
30-min preincubation 
(Shitara et al., 2004) 
(Ogilvie et al., 2006) 
 
CYP2C9 IC50 30 µM 
Ki 5.8 µM 
Ki 18.6 µM  
(Ogilvie et al., 2006) 
(Wen et al., 2001) 
(Fujino et al., 2003) 
NS at 300 µM (Ogilvie et al., 2006) 
CYP2C19 IC50 100 µM 
Ki 24 µM 
(Ogilvie et al., 2006) 
(Wen et al., 2001) 
NS at 300 µM (Ogilvie et al., 2006) 
CYP2D6 NS at 250 µM  (Wen et al., 2001) -  
CYP2E1 NS at 250 µM (Wen et al., 2001) -  
CYP3A4 NS at 250 µM 
Ki 171 µM 
IC50 372 µM 
NS at 300 µM 
(Wen et al., 2001) 
(Fujino et al., 2003) 
(Shitara et al., 2004) 
(Ogilvie et al., 2006) 
IC50 243 µM 
NS at 300 µM 
(Shitara et al., 2004) 
(Ogilvie et al., 2006) 
UGT IC50 354 µM in 
HLM* 
IC50 113 µM** 
(Prueksaritanont et al., 
2002) 
(Gan et al., 2010) 
IC50 130 µM after a 
25-min preincubation 
in HLM** 
(Gan et al., 2010) 
UGT1A1 -  IC50 69 µM after a 
25-min preincubation 
(Gan et al., 2010) 
MRP2 IC50 > 250 µM 
NS at 100 µM 
(Yamazaki et al., 2005) 
(Nakagomi-Hagihara et 
al., 2007b) 
NS at 100 µM (Nakagomi-Hagihara 
et al., 2007b) 
NTCP IC50 23µM (Ho et al., 2006) -  
OAT3 IC50 6.8 µM (Nakagomi-Hagihara et 
al., 2007a) 
19.7 µM (Nakagomi-Hagihara 
et al., 2007a) 
OATP1B1 IC50 72.4 µM 
Ki 4 µM  
Ki 12.5 µM 
Ki 25.2 µM 
IC50 25 µM 
Ki 31.7 µM 
 




(Shitara et al., 2004) 
(Schneck et al., 2004) 
(Yamazaki et al., 2005) 
(Hirano et al., 2006) 
(Ho et al., 2006) 
(Nakagomi-Hagihara et 
al., 2007b) 
(Noé et al., 2007) 
IC50 24.3 µM 
Ki 22.6 µM 
Ki 15.7 µM 
(Shitara et al., 2004) 
(Hirano et al., 2006) 
(Nakagomi-Hagihara 
et al., 2007b) 
OATP1B3 NS at 100 µM 
62% inhibition at  
200 µM  
(Ho et al., 2006) 
(Noé et al., 2007) 
-  
OATP2B1 IC50 8µM 
70% inhibition at  
200 µM 
(Ho et al., 2006) 
(Noé et al., 2007) 
-  
P-gp IC50 > 250 µM (Yamazaki et al., 2005) -  
-, data not available; MRP2, multidrug resistance-associated protein 2; NS, no significant inhibition (< 50%); 
NTCP, sodium-dependent taurocholate cotransporting polypeptide; OAT3, organic anion transporter 3; OATP, 
organic anion-transporting polypeptide; P-gp, P-glycoprotein; *, inhibition of simvastatin glucuronidation in 
human liver microsomes (at least UGT1A1 and UGT1A3 involved); **, inhibition of repaglinide 
glucuronidation in human liver microsomes (at least UGT1A1 and UGT1A3 involved). 
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The pharmacokinetic interactions caused by gemfibrozil may be mediated by several 
mechanisms. Both parent gemfibrozil and gemfibrozil 1-O-β-glucuronide can interfere with 
drug metabolism and transport. Reported in vitro inhibitory effects of gemfibrozil and 
gemfibrozil 1-O-β-glucuronide on some enzymes and transporters are provided in Table 10. 
In vitro, the inhibitory effect of gemfibrozil on CYP2C9 is more potent than on CYP2C8. In 
addition to the in vitro inhibitory effects shown in Table 10, gemfibrozil has been reported to 
induce at least CYP2C8, CYP3A4 and UGT1A1 in vitro (Prueksaritanont et al., 2005). 
 
In vivo gemfibrozil increases the AUC of a number of CYP2C8 substrate drugs such as 
repaglinide (AUC increased by 8.1-fold compared to control), cerivastatin (5.6-fold), 
montelukast (4.5-fold), pioglitazone (3.2-3.4-fold), rosiglitazone (2.3-fold), and loperamide 
(2.2-fold) (Niemi et al., 2003a; Deng et al., 2005; Jaakkola et al., 2005; Niemi et al., 2005; 
Niemi et al., 2006; Karonen et al., 2010), but it did not increase the AUC of CYP2C9 
substrate warfarin (Lilja et al., 2005). The mechanism-based inhibition of CYP2C8 by 
gemfibrozil 1-O-β-glucuronide can probably explain the differences in in vitro and in vivo 
potencies of CYP2C8 and CYP2C9 inhibition by gemfibrozil (Ogilvie et al., 2006).  
 
The AUC of other drugs has also increased with concomitant gemfibrozil administration in 
vivo. E.g., atorvastatin AUC increased by 1.2-1.4-fold, and moderate increases were seen also 
in the AUCs of atorvastatin metabolites (Backman et al., 2005; Whitfield et al., 2011). 
Similarly, the AUC of simvastatin increased by 1.4-fold and its acid metabolite by 2.5-fold; 
the AUC of active lovastatin acid increased by 2.8-fold and that of pravastatin by 2.0-fold 







Repaglinide is an oral insulin secretagogue of the meglitinide class. It was developed to be 
used in the treatment of type II diabetes, either as monotherapy or combined with other oral 
antihyperglycaemic agents such as metformin, in the 1990’s (Guay, 1998). Repaglinide was 
approved for clinical use in the United States in 1997 and in Europe in 2001. Repaglinide 
closes the adenosine triphosphate (ATP)-dependent potassium channels in the pancreatic β-
cells, which leads to the depolarisation of the cell and the subsequent activation of voltage-
dependent calcium channels. Thereafter calcium can enter the cells and initiate insulin 
secretion (Gromada et al., 1995). The basic characteristics of repaglinide are shown in Table 
11.  
 
Table 11. Characteristics of repaglinide (Guay, 1998; van Heiningen et al., 1999; Plum et al., 2000; 
Dornhorst, 2001; Hatorp, 2002; Powers and D'Alessio, 2010). 
Chemical structure  S (+) 2-ethoxy-4- [2-oxo-2-[(α-isobutyl-2-piperidinobenzyl) 
amino] ethyl]-benzoic acid, C27H36N2O4
Molecular weight 452.6 
Usual daily dosage 0.5 – 4 mg 4 times daily (before meals) 
Oral bioavailability (F) ~60% 
t1/2 1-1.5 h 
Plasma protein binding 98.5% (mainly to albumin) 
Volume of distribution (Vd) 31 l 
Metabolism CYP2C8 and CYP3A4 
Route of excretion Metabolites: biliary (90%), urinary (8%); as unchanged (2%) 
 
10.1. Repaglinide metabolism, interactions and pharmacogenomics 
 
Repaglinide is metabolised mainly by CYP2C8 and CYP3A4 to inactive metabolites 
(Bidstrup et al., 2003; Kajosaari et al., 2005a). The metabolites include M1 (an aromatic 
amine; ~4% of dose), M2 (an oxidised dicarboxylic acid; ~66% of dose) and M4 (formed via 
hydroxylation of the piperidine ring; ~1% of dose). Approximately 87% of the repaglinide 
dose is biotransformed through oxidative metabolism (Bidstrup, 2006). The main metabolic 
routes of repaglinide in vitro are shown in Figure 8. The formation of M2 has been proposed 
to be a multi-step reaction mediated by CYP3A4 and an unknown cytosolic enzyme (Gan et 
al., 2010). Also low quantities of other metabolites such as glucuronides formed by UGT1A1 
have been detected in vitro (Gan et al., 2010). CYP2C8 is considered as the most important 
enzyme in repaglinide metabolism; the fraction metabolised by CYP2C8 (fm,CYP2C8) has been 








































Figure 8. Chemical structures of repaglinide, its M1, M2 and M4 metabolites and principal enzymes 
catalysing the reactions in vitro (van Heiningen et al., 1999; Bidstrup et al., 2003; Kajosaari et al., 
2005a; Kajosaari et al., 2005b; Gan et al., 2010). 
 
 
CYP2C8 inhibitors gemfibrozil and trimethoprim inhibit repaglinide metabolism both in vitro 
and in vivo. In in vitro studies, the IC50 values of gemfibrozil and trimethoprim have been 
estimated to be 111 µM and 129 µM, respectively (Niemi et al., 2004; Kajosaari et al., 
2005a). In vivo, gemfibrozil and trimethoprim have increased the AUC of repaglinide by 8.1- 
and 1.6-fold, respectively (Niemi et al., 2003b; Niemi et al., 2004). The formation of 
CYP2C8-dependent repaglinide metabolite M4 decreases (Tornio et al., 2008a) and that of 
CYP3A4-dependent metabolite M1 increases (Niemi et al., 2003b) with gemfibrozil 
administration. The CYP2C8 genotype also affects repaglinide pharmacokinetics. The plasma 
concentrations of repaglinide are smaller in carriers of the CYP2C8*3 allele than in 
noncarriers. It has been shown that repaglinide AUC was 45% lower in subjects with the 
CYP2C8*1/CYP2C8*3 genotype compared to the CYP2C8*1/CYP2C8*1 genotype (Niemi et 
al., 2003c). However, this finding has not been confirmed in two other studies (Bidstrup et 
al., 2006; Tomalik-Scharte et al., 2011). 
 
CYP3A4 inhibitors also inhibit repaglinide metabolism, although the increases in repaglinide 
AUC with them have been smaller than with CYP2C8 inhibitors. In clinical drug-drug 
interaction studies clarithromycin and grapefruit juice, which are mechanism-based inhibitors 
of CYP3A4, increased the AUC of repaglinide only by 1.4- and 1.13-fold, respectively 
(Niemi et al., 2001; Bidstrup et al., 2006). Ketoconazole, itraconazole and telithromycin, 
reversible inhibitors of CYP3A4, increased the repaglinide AUC by 1.15-, 1.4- and 1.8-fold, 
respectively (Hatorp et al., 2003; Niemi et al., 2003b; Kajosaari et al., 2006). The formation 
of CYP3A4-dependent metabolite M1 decreased markedly compared to control in these 
studies (Kajosaari et al., 2006; Niemi et al., 2006). Interestingly, the concentrations of M2, 
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also proposed to be formed by CYP3A4, did not decrease with concomitant treatment of 
CYP3A4 inhibitor telithromycin (Kajosaari et al., 2006). When combining itraconazole with 
gemfibrozil to achieve an inhibition of both CYP3A4 and CYP2C8, a 19.4-fold increase in 
the repaglinide AUC was seen. The concentrations of M1 were decreased by the combination 
(Niemi et al., 2003b). 
 
Rifampicin, a classic enzyme inducer, has been shown to both induce and competitively 
inhibit repaglinide metabolism by CYP3A4 and CYP2C8 (Niemi et al., 2000; Kajosaari et al., 
2005a) and to inhibit OATP1B1 (Benet, 2009). As competitive inhibition starts and stops 
quickly according to the changes in the inhibitor concentrations, and induction is a relatively 
slow process; the in vivo effects of rifampicin on repaglinide pharmacokinetics depend on the 
time interval with the administration of the drugs. When repaglinide was taken 
simultaneously with the last dose of a 7-day course of rifampicin, the AUC of repaglinide was 
decreased by 50%. When rifampicin was discontinued earlier, already 24 h before repaglinide 
intake, repaglinide AUC was decreased even more, by 80%. This was proposed to be due to 
the rapid disappearance of the inhibitory effect of rifampicin, whilst induction was still 
present (Bidstrup et al., 2004). 
 
The hepatic transporter organic anion-transporting polypeptide 1B1 (OATP1B1), encoded by 
the solute carrier organic anion transporter 1B1 (SLCO1B1) gene in chromosome 12p12, 
participates in the uptake of repaglinide from blood to hepatocytes (Niemi et al., 2011). 
Therefore, changes in the OATP1B1 activity, e.g., due to concomitant drugs or genetic 
factors, may affect repaglinide pharmacokinetics. Gemfibrozil and gemfibrozil 1-O-β-
glucuronide both inhibit OATP1B1 (Shitara et al., 2004). Polymorphisms in the SLCO1B1 
gene have also been shown to affect repaglinide pharmacokinetics (Kalliokoski et al., 2008a). 
SLCO1B1*5 and *15 have been associated with decreased transport activity, whilst 
SLCO1B1*1B has been associated with increased activity. These changes in transport activity 
have been associated with increased and decreased repaglinide plasma concentrations, 
respectively. Decreased OATP1B1 activity increases also the concentrations of M2 and M4 
(Kalliokoski et al., 2008a; Kalliokoski et al., 2008b; Kalliokoski and Niemi, 2009).  
 
In addition, OATP1B1 inhibitor cyclosporine, which is also a CYP3A4 inhibitor, has 
increased the AUC of repaglinide 2.4-fold (Kajosaari et al., 2005b; Backman et al., 2006). 
Concurrently, the urinary excretion of unchanged repaglinide and metabolites M2 and M4 
increased by 2.7-, 7.5- and 5.0-fold, respectively. The urinary excretion of CYP3A4-
dependent metabolite M1 was not affected, although the M1/repaglinide ratio decreased by 
62% (Kajosaari et al., 2005b). The potential of cyclosporine to inhibit P-glycoprotein is not 
considered to affect repaglinide disposition, as repaglinide has been shown not to be a P-
glycoprotein substrate (Kajosaari et al., 2005b). 
 
Currently, there is no clear evidence that repaglinide would interfere with the metabolism or 
transport of other drugs (Scheen, 2007). There are some reports suggesting that repaglinide 
might inhibit the OATP- or organic cation transporter (OCT) -mediated transport of some 
compounds (Bachmakov et al., 2008). 
  
 47
AIMS OF THE STUDY 
 
 
The aim of this study was to characterise the time- and dose-dependency of the effect of 
gemfibrozil on the pharmacokinetics of repaglinide in order to elucidate the mechanism-based 
inhibitory effect of gemfibrozil on CYP2C8 in humans. The specific aims of the study were: 
 
 
1. To study the onset of mechanism-based inhibition of CYP2C8 by gemfibrozil in 
humans. 
 
2. To study the persistence of CYP2C8 inhibition caused by gemfibrozil in humans. 
 
3.  To study the dose relationship of CYP2C8 inhibition caused by gemfibrozil in 
humans. 
 
4.  To obtain new data concerning CYP2C8 turnover and the CYP2C8 inactivation 
potency of gemfibrozil, for use when assessing CYP2C8 related drug interaction 
potential of new chemical entities. 
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MATERIALS AND METHODS 
 
 
This work was carried out as four in vivo clinical drug-drug interaction studies at the 
Department of Clinical Pharmacology, University of Helsinki. The study protocols were 
approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital 
District, by the Helsinki University Central Hospital (HUCH) and by the Finnish National 




The subjects in the studies were healthy volunteers. Before entering the studies, they had been 
given both oral and written information and they had given a written informed consent. 
 
The number of subjects in the studies was estimated to be sufficient to detect a 30% 
difference between the phases in the AUC0-∞ of repaglinide with a power of > 80% (alpha-
level 5%). The sample size calculation for all studies ended up to 9.3 subjects / group. As the 
studies were designed as cross-over studies (all subjects completing all phases), a sample size 
of 10 was chosen for studies I, II and III. For balancing reasons (four phases), and due to the 
long clinical phase (possibility of drop-outs), altogether 12 subjects entered study IV (Table 
12). 
 
One subject participated in both studies I and II. Four subjects participated in both studies III 
and IV. One subject was excluded from the analyses due to suspected non-compliance of the 
study protocol (II) and two subjects discontinued their participation due to reasons not related 
to the study (IV). The analyses were based on the data of 39 (27 male and 12 female) subjects 
(Table 12). 
 
Table 12. Characteristics of the subjects included in the analyses. 
Study Subjects n 
(male/female) 
Age (y) Weight (kg) Body mass index 
(kg/m2) 
I 10 (5/5) 26 ± 4 72 ± 16 24 ± 4 
II 9 (7/2) 22 ± 2 77 ± 9 24 ± 2 
III 10 (9/1) 23 ± 2 73 ± 10 23 ± 2 
IV 10 (6/4) 24 ± 3 75 ± 9 25 ± 2 
Age, weight and body mass index are presented as mean ± standard deviation (SD). 
 
 
The subjects were ascertained to be healthy by medical history, clinical examination and 
routine laboratory tests. None of the subjects was using continuous medication or oral 
contraception, or was a smoker. The female subjects gave a negative pregnancy test before 
entering and during the studies. Participation in other studies and blood donation were 
prohibited 2 months before and during the studies. The use of alcohol, grapefruit and any 
medications was prohibited 1 week, and rigorous physical exercise 1 day prior to each study 
day. 
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2. Study design 
 
Studies I and II were designed to evaluate the time effects and studies III and IV the dose 
effects of gemfibrozil on CYP2C8 inhibition. All four studies were of randomised, balanced 
and cross-over design. Studies I and II assessing the time effect were open-label, whilst 
studies III and IV assessing the dose effect were double-blinded. In all studies, a small 0.25 
mg dose of repaglinide was used as an in vivo probe for CYP2C8 activity. The studies 
differed from each other by the gemfibrozil pre-treatment. Wash-out periods of 2-3 weeks 
between the phases were held in order to prevent carry-over effect. Details of the study 
designs are given in Table 13.  
 
 
Table 13. Study designs. 
Study Phases (n) Blinding Control phase Gemfibrozil 
pretreatment dosing 
Pretreatment timing 
I 5 Open Repaglinide 
alone 
Gemfibrozil single 
dose 600 mg 
0, 1, 3 or 6 h before 
repaglinide 
II 5 Open Repaglinide 
alone 
Gemfibrozil 600 mg 
twice daily for 3 
days 
Last pre-treatment 
dose 1, 24, 48 or 96 
h before repaglinide 
III 5 Double-blinded Repaglinide 
with placebo 
Gemfibrozil single 
dose 30, 100, 300 or 
900 mg 
Pretreatment 1 h 
before repaglinide 
IV 4 Double-blinded Repaglinide 
with placebo 
Gemfibrozil 30, 100 
or 600 mg twice 
daily for 5 days 
Last pre-treatment 




2.1. Study drugs 
 
For safety reasons, a small 0.25 mg dose of oral blood glucose lowering drug repaglinide was 
used as an in vivo probe for CYP2C8 activity. NovoNorm 0.5 mg tablets (Novo Nordisk, 
Bagsværd, Denmark) provided by the HUCH pharmacy were halved and weighed by the 
same investigator for all studies. For halving the tablets, in each study, 10 tablets were 
weighed together, and by dividing the mass by 20, a target mass for the tablet halves was 
obtained. Subsequent tablet halves with a maximum of one percent (1%) deviation from this 
target mass were accepted for use in the study. After halving the tablets for each study, the 
tablet halves were organised in order of increasing weight, and every subject received tablet 
halves of approximately the same weight. 
 
For gemfibrozil pre-treatment in studies I and II Lopid 600 mg tablets (Gödecke, Freiburg, 
Germany) were provided by the HUCH pharmacy. For studies III and IV, gemfibrozil and 
placebo capsules were prepared using methods described in the European Pharmacopoeia (Ph. 
Eur.) by the HUCH Pharmacy. The gemfibrozil content of the capsules was measured using 
the liquid chromatography–tandem mass spectrometry system. The randomisation for all 
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studies was done by the HUCH Pharmacy. The blinding codes for studies III and IV were 
opened after the clinical phase of the studies. 
 
Gemfibrozil/placebo capsules were supplied to the subjects in advance in studies I, II and IV. 
Gemfibrozil/placebo capsules in study III and repaglinide tablets in all studies were 
administered to the subjects in the study premises. 
2.2. Study conduct 
 
The study days (n = 46) started at 7:30 in the morning with insertion of intravenous forearm 
cannules to the subjects. During the study days, the subjects were under direct medical 
supervision. Blood sampling and drug administration started at 8:00. 
 
The study drugs were administered orally after an overnight fastening with 100 ml (with pre-
treatment) and 150 ml (with repaglinide) water. The subjects remained seated until 12:00 in 
order to keep the conditions for drug absorption as identical as possible. 
 
Timed blood samples (5 or 10 ml each) were drawn from a cannulated forearm vein 60, 30 
and 5 min before and at 15, 30, 45, 60, 80 and 100 min, and 2, 2.5, 3, 4, 5, 7 and 9 h after the 
administration of repaglinide into ethylenediaminetetraacetic acid (EDTA) containing tubes. 
In study II, blood samples for the determination of gemfibrozil and gemfibrozil 1-O-β 
glucuronide concentrations were also taken during the 96 h timing interval (25, 49 and 73 h 
before repaglinide intake) and during the 48 h timing interval (25 h before repaglinide intake). 
Plasma was separated within 30 min and stored at -70ºC until analysis. 
 
From samples taken 5 min before and at 15, 30, 45, 60, 80 and 100 min, and 2, 2.5, 3, 4, 5, 7 
and 9 h after the administration of repaglinide blood glucose concentrations were measured 
immediately after sampling. The measurement was made by a Precision G Blood Glucose 
Testing System (Medisense, Bedford, MA) in studies I and II, and by a Precision Exceed 
device (Abbott Diabetes Care Ltd, Witney Oxon, UK) in studies III and IV.  
 
The last samples for pharmacokinetic analyses were taken at 18:00. If the subjects’ blood 
glucose levels were equal to or exceeded the predefined safety level (4.0 mmol/l), the study 
day was regarded as ended and the subjects were allowed to leave the study premises. In other 
cases, additional carbohydrates were provided and blood glucose levels were monitored until 
reaching the safe minimum level. 
 
Food intake was identical during all study days to provide accuracy for pharmacodynamic 
data (blood glucose levels). The meals comprised a standardised light breakfast 15 min after 
repaglinide administration (eaten over duration of 10 min), carbohydrate-rich snacks after 1 
and 2 h (eaten over duration of 5 min), a warm meal after 3 h, and snacks after 7 and 9 h. 
 
Additional carbohydrates, glucose solution for intravenous use and glucagon for 





For genotyping, a 12-20 ml EDTA blood sample was drawn from each subject and stored at -
20°C. Genomic deoxyribonucleic acid (DNA) was extracted with standard methods (Qiaamp 
DNA Blood Mini Kit, Qiagen, Hilden, Germany). The subjects were genotyped for the 
CYP2C8*1 (wild type), CYP2C8*3 (c.416G>A and c.1196A>G) and CYP2C8*4 (c.792C>G) 
alleles and the SLCO1B1*1A (wild type) and SLCO1B1 c.388A>G and c.521T>C single 
nucleotide polymorphisms (SNP), defining the SLCO1B1*1B (GT), *5 (AC), and *15 (GC) 
haplotypes (Kalliokoski and Niemi, 2009), with TaqMan® genotyping assays on an Applied 
Biosystems 7300 Real-Time PCR system (Pasanen et al., 2006). The CYP2C8 and SLCO1B1 
genotypes of the subjects included in the analyses are presented in Table 14. 
 
 
Table 14. Numbers of different CYP2C8 and SLCO1B1 genotype carriers in the studies. 
Study CYP2C8 genotype (n of subjects) SLCO1B1 genotype (n of subjects) 





























3. Determination of drug concentrations 
3.1. Repaglinide and its metabolites 
 
Concentrations of repaglinide and its metabolites M1, M2, and M4 were measured in plasma 
samples by use of an API 3000 liquid chromatography–tandem mass spectrometry system 
(Sciex Division of MDS, Toronto, Ontario, Canada) (Tornio et al., 2008a). The limit of 
quantification for repaglinide was 0.01 ng/ml in all studies. In all studies except II, the limit of 
quantification for repaglinide M1 and M2 was 0.02 ng/ml. Because an authentic metabolite 
standard for M4 was not available, M4 concentrations are given in arbitrary units (units per 
millilitre) relative to the ratio of the peak height of M4 to that of the internal standard in the 
chromatogram. The limit of quantification for M4 was based on a signal-to-noise ratio of 
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more than 10:1. This approach was used also for M1 and M2 in study II. Gemfibrozil or its 
glucuronide did not interfere with the assays.  
3.2. Gemfibrozil and gemfibrozil 1-O-β-glucuronide 
 
The plasma concentrations of gemfibrozil and gemfibrozil 1-O-β-glucuronide were 
determined by the use of the Applied Biosystems API 2000 Q Trap liquid chromatography–
tandem mass spectrometry system (Sciex Division of MDS, Toronto, Ontario, Canada) using 
a modification of a previous method (Roadcap et al., 2003). Gemfibrozil-d6 and gemfibrozil 
1-O-β-glucuronide-d6 served as internal standards. The limits of quantification for 
gemfibrozil and gemfibrozil 1-O-β-glucuronide were 0.0025 mg/l in all studies. 
 
4. Pharmacokinetic calculations 
 
The pharmacokinetics of repaglinide and its metabolites M1, M2, and M4 were characterised 
by the peak concentration (Cmax), AUC0-9h and AUC0-∞ (AUC0-3h for M4) and elimination 
half-life (t½). The terminal log-linear part of each concentration-time curve was identified 
visually. The elimination rate constant (ke) was determined by linear regression analysis of the 
log-linear part of the plasma concentration-time curve. The t½ was calculated by the equation 
t½ = ln2/ke. The AUC values were calculated by use of the linear trapezoidal rule for the rising 
phase of the plasma repaglinide concentration-time curve and the log-linear trapezoidal rule 
for the descending phase, with extrapolation to infinity, when appropriate, by dividing the last 
measured concentration by ke. In addition, in study II, the oral clearance (CL/F) of repaglinide 
was calculated by dividing its dose (0.25 mg) with its AUC0-∞.  
 
The pharmacokinetics of gemfibrozil and gemfibrozil 1-O-β-glucuronide were characterised 
by concentration at different times (Ct), Cmax, time to Cmax (tmax), t½ and different AUC0-t. The 
elimination rate constant (ke) was determined by linear regression analysis of the log-linear 
part of the plasma concentration-time curve. In study IV, the C12 and AUC0-12h were 
extrapolated from C10 and AUC0-10h using the ke. In addition, the average concentrations 
(Cavg,0-t) were calculated by dividing the AUC0-t by time (t). In study II, Cavg,0-9h; in study III, 
Cavg,0-10h and in study IV, Cavg,0-12h were calculated. 
 
The pharmacokinetics were calculated by noncompartmental analysis using WinNonlin, 
version 5.2 (Pharsight Inc., Mountain View, CA) for study II, and MK-Model, version 5.0 
(Biosoft, Cambridge, UK) for studies I, III and IV. 
 
5. Pharmacodynamic calculations 
 
The pharmacodynamics of repaglinide was measured by changes in blood glucose levels. 
They were characterised by baseline (i.e. before administration of repaglinide), minimum and 
mean blood glucose concentration (from 0 to 3 and 9 h). The mean blood glucose 
concentrations were calculated by dividing the area under the blood glucose concentration-
time curve by the corresponding time interval. 
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6. Statistical analyses 
 
Pharmacokinetic and pharmacodynamic variables between the phases were tested using a 
paired t-test, or in the case of tmax, by the Wilcoxon signed-rank test. Before statistical testing, 
pharmacokinetic variables in studies I and IV were log-transformed, when appropriate. To 
avoid false negative conclusions and because the direction of the interaction has been 
documented previously, no Bonferroni correction for multiple comparisons was applied. 
Differences were therefore considered statistically significant at P < 0.05 in all studies. 
 
In studies III (single dose) and IV (multiple dose) the dose-proportionality of gemfibrozil 
pharmacokinetics was estimated by regression analysis with the power-model approach using 
a logarithmically transformed form of the equation:  
 
βα ⋅= doseeAUC  
 
after logarithmic transformation of the gemfibrozil and its glucuronide AUC0-∞ data (study 
III) or AUC0-12h data (study IV). In this approach a statistically significant deviation of the 
term β from unity indicated dose non-linearity. 
 
Studies I and II were analysed with SPSS for Windows, version 16.0.1 (SPSS Inc, Chicago, 
IL) and studies III and IV with PASW for Windows, version 17.0 (SPSS Inc, Chicago, IL). 
 
7. Application of physiological concepts and models to in vivo interaction data 
using regression analyses 
7.1. Estimation of CYP2C8 turnover half-life 
 
Using the extent of the interaction (fractional decrement in oral clearance (FDCL) from 
repaglinide AUCinhibited/AUCcontrol data) at different time points after stopping gemfibrozil 
administration, the first-order degradation rate constant of CYP2C8 was estimated in study II. 
The interaction data from time points 24, 48 and 96 h obtained in the study were used for the 
analysis. The time point for the control phase representing full recovery of the enzyme 
activity was set to 10,000 h. For the estimation, the oral clearance (CL/F) of repaglinide was 
described with the following equation:  
 
( ) ( ) eredcovrehtkeredcovre FCLeFDCLFCLtFCL deg ⋅⋅−= −⋅− 2424  
 
where CL/Frecovered is the CL/F of repaglinide when CYP2C8 activity is fully recovered, 
FDCL24 is the fractional decrement in the CL/F of repaglinide when repaglinide is 
administered at 24 h after the last dose of gemfibrozil, kdeg is the first-order degradation rate 
constant of CYP2C8, and t is the time after the last dose of gemfibrozil. This equation was 
fitted to the data from the study by non-linear regression analysis, with the estimation of kdeg. 
From the k obtained, the degradation half-life of CYP2C8 was calculated using the equation 
t½ = ln2/kdeg. 
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7.2. Pharmacokinetic modelling 
 
Pharmacokinetic modelling was done to evaluate the repaglinide fraction metabolised by 
CYP2C8 (fmCYP2C8), intrahepatic inhibitor (gemfibrozil / gemfibrozil 1-O-β-glucuronide) 
concentrations and to confirm the mechanism-based inhibition of CYP2C8 to be the main 
mechanism for repaglinide-gemfibrozil interaction. Also, the contribution of possible 
OATP1B1 inhibition to this interaction was examined by mathematical modelling. 
 
Several static enzyme and transporter inhibition models were applied to the relationship 
between the plasma concentrations of gemfibrozil or its 1-O-β-glucuronide and the increase in 
the AUC of repaglinide in the studies III and IV. Previously published IVIVE equations were 
fitted to the repaglinide AUC fold increase data (Mayhew et al., 2000). In vitro constants for 
CYP2C8 (kinact 0.21 min-1, KI 20 µM) and OATP1B1 inhibition (IC50 24.3 and 72.4 µM for 
gemfibrozil and its glucuronide, respectively) published in literature (Shitara et al., 2004; 
Ogilvie et al., 2006; Hinton et al., 2008) were used in the calculations. Also, the degradation 
rate constant for CYP2C8 (kdeg) obtained from study II was used in the models including a 
mechanism-based inhibition component. The ratio of unbound hepatocyte concentration vs. 
total plasma concentration (Ch,u/Cp,tot) of gemfibrozil or its glucuronide, repaglinide fm,CYP2C8 
and fraction transported by OATP1B1 (ft,OATP1B1) were left as unknown parameters to be 
predicted with non-linear regression analysis. The fit of the models (coefficient of 
determination, r2) and the sanity of the estimated parameters were used for assessing the 
possibility of the tested interaction mechanism to explain the observed repaglinide AUC fold 
increase. In some cases, predefined, meaningful constraints for the parameters to be estimated 
were used in the regression analyses (e.g., 0 ≤ fm,CYP2C8 ≤ 1). The equations tested are 
presented in Table 15. 
 
Table 15. Equations used in the non-linear regression analyses concerning the dose-dependency of 
gemfibrozil-repaglinide interaction in studies III and IV. 
Inhibitor and inhibition type Equation (AUC fold increase =) 
Gemfibrozil 1-O-β-glucuronide  
mechanism-based CYP2C8 1/[(fm,CYP2C8/(1+kinact/KI·[I]h/kdeg))+1-fm,CYP2C8] 
competitive OATP1B1 1/[(ft,OATP1B1/(1+[I]h/Ki))+1-ft,OATP1B1] 
mechanism-based CYP2C8 + competitive OATP1B1 (1/[(fm,CYP2C8/(1+kinact/KI·[I]h/kdeg))+1-fm,CYP2C8]) 
·(1/[(ft,OATP1B1/(1+[I]p,u/Ki))+1-ft,OATP1B1]) 
Gemfibrozil  
competitive CYP2C8 1/[(fm,CYP2C8/(1+[I]h/Ki))+1-fm,CYP2C8] 
competitive OATP1B1 1/[(ft,OATP1B1/(1+[I]h/Ki))+1-ft,OATP1B1] 
fm,CYP2C8, fraction metabolised by CYP2C8; ft,OATP1B1, fraction transported by OATP1B1; [I]h, inhibitor 
concentration in the liver; [I]p,u, plasma unbound inhibitor concentration  
 
 
In the equations, both average and peak plasma concentrations gemfibrozil and gemfibrozil 1-
O-β-glucuronide were used separately. As the potential of competitive inhibition of CYP2C8 
by gemfibrozil 1-O-β-glucuronide has been shown to be very weak compared to mechanism-
based inhibition (Shitara et al., 2004), a model testing this inhibition type was not applied. 
 55
From equations including only one inhibition mechanism, the model providing the best fit 
(mechanism-based inhibition model) was also used for individual data. This was done both in 
studies III and IV. From this analysis, individual fm,CYP2C8 and Ch,u/Cp,tot values were obtained. 
 
To examine, whether adding an OATP1B1 inhibition component to the mechanism-based 
CYP2C8 inhibition model would increase the fit of the models (r2), a combined reversible 
OATP1B1 inhibition and time-dependent CYP2C8 inhibition model was also applied. This 
was done both in studies III and IV. The following equation was used:  
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From this analysis, estimates for fm,CYP2C8, ft,OATP1B1 and Ch,u/Cp,tot were obtained. 
 
7.3. Estimation of remaining CYP2C8 activity and in vivo AUC ratios of CYP2C8 
substrates with different gemfibrozil doses and different fm,CYP2C8 
 
Using the gemfibrozil dose-proportionality data (α, β) and the scaling factor for intrahepatic 
gemfibrozil 1-O-β-glucuronide (Ch,u/Cp,tot) obtained in study IV (multiple dosing), kdeg 
obtained from study II and previously published inhibition constants (kinact and KI), an 
estimation of the in vivo AUC ratios (AUCinhibited/AUCcontrol) for substrate drugs of different 
fractions metabolised by CYP2C8 when treated with different gemfibrozil doses twice daily 
was done. The following equation with fm,CYP2C8 values of 99%, 95%, 90%, 80%, 70% and 


































where t is the time of dosing interval of gemfibrozil (12 h). 
 
In addition, estimates of the remaining CYP2C8 activity with different doses of gemfibrozil 
















In this section, the main results of studies I-IV are presented. All pharmacokinetic data are 
presented here as fold changes of geometric means, although the original publications for 
studies II and III present fold changes of arithmetic means of the variables. 
 
1. Onset of CYP2C8 inhibition (I) 
 
CYP2C8 enzyme inhibition in vivo, reflected as changes in repaglinide metabolism in healthy 
volunteers, started rapidly after oral gemfibrozil administration. The changes in the 
concentrations of repaglinide and its metabolites were greatest when repaglinide was taken 1 
or 3 h after gemfibrozil. 
 
The geometric mean AUC0-∞ of repaglinide was 5.0-, 6.3-, 6.6- and 5.4-fold compared to 
control (i.e., no gemfibrozil) when gemfibrozil was taken simultaneously with and 1, 3 and 6 
h before repaglinide, respectively (Figure 9; P < 0.001). The Cmax of repaglinide increased by 








Figure 9. Fold changes in the AUC of repaglinide and its metabolites compared to the control phase, 
when a single 600 mg dose of gemfibrozil was taken simultaneously or 1, 3 or 6 h before repaglinide 
intake. For repaglinide M4, AUC0-3h data is presented. For all other compounds, AUC0-∞ data is 
presented. 
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The formation of CYP3A4-dependent repaglinide metabolite M1 increased in the phases with 
gemfibrozil pretreatment. The AUC0-∞ of repaglinide M1 was 4.4-, 4.4-, 4.1- and 3.1-fold 
compared to the control phase, respectively (Figure 9; P < 0.001). The AUC0-∞ of repaglinide 
M2 was 1.2-, 1.3-, 1.3- and 1.3-fold, respectively (Figure 9; P < 0.05 in the 3 and 6 h dosing 
intervals). The formation of the CYP2C8-dependent repaglinide metabolite M4 was 
significantly impaired by gemfibrozil pretreatment. The AUC0-3h of M4 was 85%, 16%, 12% 
and 15% of control when gemfibrozil was taken simultaneously with and 1, 3 and 6 h before 
repaglinide, respectively (Figure 9; P < 0.001 in the 1, 3 and 6 h dosing intervals). The 
M4/repaglinide AUC0-3h ratio was 31%, 4%, 3% and 4% of control in the 0, 1, 3 and 6 h 
interval phases, respectively (P < 0.001 in the 1, 3 and 6 h dosing intervals). 
 
2. Duration/persistence of CYP2C8 inhibition (II) 
 
CYP2C8 inhibition was shown to recover slowly in humans. A practically complete recovery 
of the enzymatic activity to the control level, reflected by repaglinide metabolism, was 
detected 96 h after stopping twice daily gemfibrozil administration. 
 
The geometric mean AUC0-∞ of repaglinide was 8.2-, 3.0-, 1.4- and 1.0-fold compared to 
control (i.e., no gemfibrozil) when the last dose of a 3-day gemfibrozil pretreatment with 600 
mg twice daily was taken 1, 24, 48 and 96 h before repaglinide, respectively (Figure 10; P < 
0.001 in the 1, 24 and 48 h phases). The Cmax of repaglinide was 2.7-, 1.9-, 1.2- and 1.1-fold 





Figure 10. Fold changes in the AUC of repaglinide and its metabolites compared to the control phase, 
when the last dose of gemfibrozil was taken 1, 24, 48 or 96 h before repaglinide intake. For 
repaglinide M4, AUC0-3h data is presented. For all other compounds, AUC0-∞ data is presented. 
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The AUC0-∞ of CYP3A4-dependent repaglinide metabolite M1 was 4.7-, 1.7-, 1.2- and 1.0-
fold compared to the control phase, when the last dose of a 3-day gemfibrozil pretreatment 
with 600 mg twice daily was taken 1, 24, 48 and 96 h before repaglinide, respectively (Figure 
10; P < 0.05 in the 48 h phase, P < 0.001 in the 1 and 24 h phases). The AUC0-∞ of 
repaglinide M2 was 2.2-, 1.5-, 1.2- and 1.1-fold compared to the control phase, respectively 
(Figure 10; P < 0.05 in the 1 and 24 h phases). The formation of the CYP2C8-dependent 
repaglinide metabolite M4 was significantly impaired only in the shortest 1 h dosing interval. 
The AUC0-3h of M4 was 11% and the Cmax 8% of the control value, when the last dose of 
gemfibrozil was taken 1 h before repaglinide, respectively (Figure 10; P < 0.001). The 
M4/repaglinide AUC0-3h ratio was 2%, 40%, 90% and 100% of control in the 1, 24, 48 and 96 
h interval phases, respectively (P < 0.001 in the 1 and 24 h dosing intervals). 
 
The gemfibrozil and gemfibrozil 1-O-β-glucuronide concentrations at the time of repaglinide 
intake were approximately 1%, 0.1% and 0.02% of the Cmax values estimated in the 1 h dosing 
interval phase, when repaglinide was taken 24, 48 and 96 h after the last gemfibrozil dose. 
 
With a mechanism-based inhibition model assuming termination of the CYP2C8 inactivating 
process within 24 h after the last gemfibrozil dose, a constant rate of CYP2C8 enzyme 
production and a first-order process of enzyme degradation, the mean first-order degradation 
rate of CYP2C8 was estimated at 0.00056 min-1 and the corresponding t½ at 22 h, when each 
subject was analysed separately. 
 
3. Dose-dependency of CYP2C8 inhibition with gemfibrozil (III and IV) 
 
Study III. The interaction between gemfibrozil and repaglinide was shown to be dose-
dependent. The results were consistent with approximately 50% inhibition of CYP2C8 
already with a single 30 mg dose of gemfibrozil, and > 90% CYP2C8 inhibition with a 900 
mg dose. 
 
The geometric mean AUC0-∞ of repaglinide was 1.7-, 4.3-, 6.5- and 8.1-fold compared to 
control (i.e., with placebo) when repaglinide was taken 1 h after a single oral dose of 30, 100, 
300 and 900 mg gemfibrozil, respectively (Figure 11, Table 16; P < 0.001). The geometric 
mean Cmax of repaglinide increased by 1.3-, 1.6-, 2.0- and 2.3-fold, respectively (P < 0.05). 
 
The concentrations of M1 increased with increasing gemfibrozil doses. The AUC0-∞ of 
repaglinide M1 was 1.1-, 1.9-, 2.9- and 4.3-fold in the 30, 100, 300 and 900 mg phases, 
compared to the control phase, respectively (Figure 11; P < 0.001 in the 100, 300 and 900 mg 
phases). The AUC0-∞ of repaglinide M2 was 1.0-, 1.1-, 1.2- and 1.5-fold compared to control, 
respectively (P < 0.05 with 300 and 900 mg doses). The formation of the CYP2C8-dependent 
repaglinide metabolite M4 was significantly impaired by gemfibrozil pretreatment. In the 900 
mg phase, M4 could not be detected in the samples of most subjects, and pharmacokinetic 
variables could not be calculated. The geometric mean AUC0-3h of repaglinide M4 was 102%, 
50% and 30% of control when taken 1 h after a single oral dose of 30, 100 and 300 mg 
gemfibrozil, respectively (P < 0.05 in the 100 mg phase, P < 0.001 in the 300 mg phase). The 
M4/repaglinide AUC0-3h ratio was 66%, 22%, and 11% of the control in the 30, 100 and 300 
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mg phases, respectively (P < 0.005 in the 30 mg phase, P < 0.001 in the 100 and 300 mg 
phases). 
 
The AUC values of gemfibrozil and its glucuronide increased slightly more than dose-
proportionally. The nonlinearity was slightly greater for the glucuronide than for the parent 
gemfibrozil, resulting in a dose-dependent increase in the glucuronide/gemfibrozil AUC-ratio. 
With the power-model approach using the equation AUC0-∞ = eα · doseβ, β was estimated at 
1.21 (95% confidence interval (CI) 1.15, 1.26) for gemfibrozil and at 1.33 (95% CI 1.28, 
1.39) for gemfibrozil 1-O-β-glucuronide. 
 
A mechanism-based inhibition model of CYP2C8 with gemfibrozil 1-O-β-glucuronide Cavg,10h 
could well explain the observed extent of the interaction (repaglinide AUCinhibited/AUCcontrol) 
in pooled data (Table 17; r2 = 0.79). Using this model, the fraction of the repaglinide dose 
metabolised by CYP2C8 (fm,CYP2C8) and the ratio of unbound hepatocyte concentration to total 
plasma concentration (Ch,u/Cp,tot) of gemfibrozil 1-O-β-glucuronide were estimated at 89% 
and 0.24, respectively. When the same model was applied to each subject separately, the 
estimates for the fm,CYP2C8 of repaglinide and the Ch,u/Cp,tot of gemfibrozil 1-O-β-glucuronide 
averaged 89% and 0.28, respectively. 
 
With a model combining mechanism-based CYP2C8 inhibition and reversible OATP1B1 
inhibition model, a slightly better fit to the observed in vivo interaction data could be achieved 
(Table 17; r2 = 0.81). With this model, the estimated fm,CYP2C8, Ch,u/Cp,tot -ratio and ft,OATP1B1 
were 84%, 0.37 and 94%, respectively. It was estimated that ~50% inhibition of CYP2C8 can 
be reached already with a single dose of 30 mg gemfibrozil, and > 90% inhibition by 




Table 16. Repaglinide geometric mean AUC0-∞ fold by gemfibrozil dosing scheme, when the only/last 




Repaglinide geometric mean AUC0-∞ fold increases with different gemfibrozil doses (and 
estimates of the level of CYP2C8 inhibition based on M4/repaglinide AUC ratios) 
30 mg 100 mg 300 mg 600 mg 900 mg 
Single dose (III) 1.7 (34%) 4.3 (78%) 6.5 (89%) - 8.1 (> 95%) 
Twice daily for 
5 days (IV) 










Figure 11. Fold changes in the AUC of repaglinide and its metabolites compared to the control phase, 
when repaglinide was taken 1 h after a single 30, 100, 300 or 900 mg dose of gemfibrozil (Study III, 
left panel) or 1 h after the last dose of 30, 100 or 600 mg gemfibrozil twice daily (Study IV, right 




Study IV. When gemfibrozil was administered twice daily for 5 days, large increases in the 
AUC of repaglinide were observed already with small gemfibrozil doses. Repaglinide 
geometric mean AUC0-∞ was increased by 3.4-, 5.5- and 7.0-fold of control after a 5-day 
pretreatment with gemfibrozil 30, 100 or 600 mg twice daily (Figure 11, Table 16; P < 0.001). 
The geometric mean Cmax of repaglinide increased by 1.5-, 1.9- and 2.0-fold, respectively (P < 
0.005). 
 
The AUC0-∞ of M1 was increased by 1.4-, 2.2- and 4.6-fold in the 30, 100 and 600 mg 
gemfibrozil phases, respectively (Figure 11; P < 0.05). The AUC0-∞ of repaglinide M2 was 
1.0-, 1.1- and 2.0-fold compared to the control phase, respectively (P < 0.001 in the 600 mg 
phase). The AUC0-3h of M4 was decreased to 74% (non-significant), 32% and 20% of control 
(P < 0.001), respectively. The M4/repaglinide AUC0-3h ratio was 28%, 9%, and 5% of control 
in the 30, 100 and 600 mg phases, respectively (P < 0.001 in all phases). 
 
With the 100 mg and 600 mg gemfibrozil doses (which are 3.3- and 20-fold compared to the 
30 mg dose, respectively) the AUC0-10h of gemfibrozil was 3.9- and 31.9-times higher than 
with the smallest 30 mg gemfibrozil dose, i.e., the AUC increased more than dose-
proportionally. The AUC0-10h of gemfibrozil 1-O-β-glucuronide increased even more, to 4.7- 
and 52.8-fold, respectively. With the power-model approach using the equation AUC0-12h = eα 
· doseβ, β was estimated at 1.16 (95% CI 1.07, 1.25) for gemfibrozil and at 1.33 (95% CI 1.24, 
1.42) for gemfibrozil 1-O-β-glucuronide. 
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A static mechanism-based inhibition model using Cavg,12h of gemfibrozil 1-O-β-glucuronide as 
the inhibitor concentration was fitted to the observed repaglinide AUC ratio data. With non-
linear regression analysis fm,CYP2C8 was predicted at 86% and Ch,u/Cp,tot of gemfibrozil 1-O-β-
glucuronide at 0.77 (Table 17; r2 = 0.634). The CYP2C8 mechanism-based inhibition model 
was also applied to individual data, which yielded a mean fm,CYP2C8 of repaglinide of 86% and 
Ch,u/Cp,tot of gemfibrozil 1-O-β-glucuronide of 0.86. Based on this analysis > 50% inhibition 
of CYP2C8 was obtained with the 30 mg gemfibrozil dose in all the subjects and at least 90% 
inhibition was reached with the 100 mg dose in 8 of the 10 subjects. 
 
 
Table 17. Predicted values of unknown parameters by the best fitting models in studies III and IV. 







Single dose CYP2C8 MBI 89% - 0.24 0.792 
Single dose CYP2C8 MBI + 
competitive 
OATP1B1 
84% 94% 0.37 0.805 
Multiple dose CYP2C8 MBI 86% - 0.77 0.634 
Multiple dose CYP2C8 MBI + 
competitive 
OATP1B1 
85% 15% 0.86 0.635 
fm,CYP2C8, fraction metabolised by CYP2C8; ft,OATP1B1, fraction transported by OATP1B1; Ch,u/Cp,tot, ratio of 
unbound hepatocyte concentration to total plasma concentration; r2, coefficient of determination 
 
 
As in study III, a combined CYP2C8 mechanism-based inhibition - competitive OATP1B1 
inhibition model using gemfibrozil 1-O-β-glucuronide Cavg,12h and Cmax, respectively, as 
inhibitor concentration yielded a slightly better fit (r2= 0.635) than the model assuming 
mechanism-based inhibition alone (Table 17). With this combination model, the Ch,u/Cp,tot, 
fm,CYP2C8 and ft,OATP1B1 were predicted at 0.86, 85% and 15%, respectively. 
 
With a mechanism-based inhibition model based on the mean Ch,u/Cp,tot obtained in study IV, 
fold increases in the AUC of drugs with different fm,CYP2C8 and the remaining CYP2C8 
activity were estimated for different gemfibrozil doses taking into account the dose-
proportionality of the AUC of gemfibrozil 1-O-β-glucuronide as described by the power 
model used. It was estimated that a 50% inhibition of CYP2C8 can be reached already by 
twice-daily administration of << 30 mg gemfibrozil, and a > 90% inhibition by administering 






1. Methodological considerations 
1.1. Study design 
 
The studies were carried out as in vivo clinical drug-drug interaction studies with a 
randomised, balanced, cross-over design. All subjects in the studies acted as their own 
controls. This was particularly important for getting reliable data on the extent of the 
interaction, as the pharmacokinetics of repaglinide, the probe drug used in these studies, has 
been shown to be highly variable between individuals (Niemi et al., 2003c). 
 
The studies examining the effect of the gemfibrozil dose (III and IV) were of placebo-
controlled design. Both the subjects and the investigators remained blinded during the clinical 
phase of the studies. Studies I and II assessing the effect of timing of gemfibrozil 
administration included also a control phase (i.e., no gemfibrozil was administered), but 
placebos were not used because the blinding would have required placebo administration at 
multiple time points, including night time administration in study I, in the gemfibrozil phases 
as well as in the control phase. In studies of 5 different schemes (intervals) of study drug 
administration, the use of placebos, and the burden of study related activities to the subjects, 
would have been too extensive. As the main results of these studies are based on 
pharmacokinetics, and only to a minor extent on pharmacodynamic variables, they can be 
considered reliable also without the use of placebo. Subjective assessments, e.g., symptoms of 
hypoglycaemia, which could be affected by the information of the actual study treatment, 
were used mainly for safety measures, not as the primary results of the studies. 
 
Both the slow recovery of enzyme activity due to mechanism-based inhibition and the half-
lives of the study drugs were considered when the wash-out periods in the studies were 
determined. To prevent carry-over effect, long (2-3 weeks in minimum) wash-out periods 
were held in all studies. 
 
Since the CYP2C8 and OATP1B1 inhibitory effects of gemfibrozil and gemfibrozil 1-O-β-
glucuronide have already been extensively studied in vitro, no in vitro studies were included 
in this work. Important inhibition constants such as kinact, KI, IC50 have been previously 
reported by other groups (Shitara et al., 2004; Ogilvie et al., 2006). However, substantial 
amount of information needed for the in vitro - in vivo extrapolation of the mechanism-based 
inhibition of CYP2C8 by gemfibrozil were missing. In addition, other information such as 
data of appropriate design of clinical drug-drug interaction studies and safer therapeutic use of 
drugs could be obtained with these in vivo studies. 
1.2. Ethical and safety considerations 
 
In the studies, gemfibrozil and repaglinide, drugs with potential pharmacological effects were 
administered to healthy volunteers. This can be justified by many arguments. Apart from the 
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potential for drug interactions, treatment with the lipid-lowering agent gemfibrozil has been 
well-tolerated and safe in clinical use. In our studies, single doses or only short, up to 5-day 
courses of gemfibrozil were used. The maximal doses used in the studies were not higher than 
the approved therapeutic doses of gemfibrozil, 900 mg once or 600 mg twice daily. Although 
concomitant use of gemfibrozil and the blood glucose lowering oral antidiabetic agent 
repaglinide is contraindicated in many countries, repaglinide was used as an in vivo probe for 
measuring CYP2C8 activity in the subjects. For safety reasons, the repaglinide dose was 
small, 0.25 mg, in all studies. It has been argued that the metabolism of repaglinide could 
differ at different doses, but this is not considered a concern in this work as the same 
repaglinide dose was used in all study phases. In addition, at least in one study, the 
metabolism of repaglinide has been shown to be unaltered over a wide dose range 
(Kalliokoski et al., 2008c). Further, in some cases, based on safety grounds, the use of smaller 
than clinical doses of the drugs are considered adequate for drug-drug interaction studies 
(Huang et al., 2007). 
 
The safety of the subjects was carefully followed in all studies. Volunteers with any signs of 
hepatic or kidney function abnormalities or other medically significant abnormalities were 
excluded from the studies. The subjects entering the studies were given proper guidance 
concerning, e.g., avoiding physical exercise before and in the evenings of the study days. 
Female subjects were routinely ascertained not to be pregnant before and during the studies, 
and also in case of a suspected possibility of pregnancy. During the study days the subjects 
were under direct medical supervision. Rescue medication and equipment were available for 
medical emergency situations. Blood glucose levels were measured frequently after 
repaglinide intake with predefined rules of actions in case of hypoglycaemia. The subjects 
were allowed to leave the study premises in the evening of the study days only after blood 
glucose had reached the predefined safety level. In case of adverse reactions, the subjects 
were rigorously followed up by the investigators. 
1.3. Selection of in vivo probe drug for CYP2C8 activity 
 
Repaglinide was chosen as the probe drug for measuring in vivo CYP2C8 activity. 
Repaglinide was considered as a proper in vivo probe for CYP2C8 activity because it is 
metabolised mainly by CYP2C8. CYP3A4 has also been shown to catalyse repaglinide 
metabolism, but it is not inhibited by gemfibrozil or its glucuronide (Backman et al., 2000; 
Shitara et al., 2004; Kajosaari et al., 2005a). In addition, the t1/2 of repaglinide is short, which 
makes it superior compared to other potential CYP2C8 probe drugs for studying time-related 
changes in enzyme activity. Repaglinide is also recommended to be used as a probe drug for 
CYP2C8 activity for in vivo studies by the regulatory authorities (FDA, 2006; EMA, 2010), 
although the blood glucose lowering effect can expose the subjects to hypoglycaemia. 
Compared to other in vivo probes for CYP2C8 activity, repaglinide has shown the best 
sensitivity for CYP2C8 activity. Pioglitazone and rosiglitazone have been less sensitive 
CYP2C8 probes than repaglinide (Lai et al., 2009). The use of other CYP2C8 probes was not 
considered reasonable either. Cerivastatin has been withdrawn from the market, which 
impairs its accessibility. Paclitaxel, an antineoplastic agent, cannot be used in healthy subjects 
due to safety reasons. Therefore, in spite of its hypoglycaemic effect, repaglinide was chosen 
as the probe drug for this work. The prevention, detection and management of the 
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hypoglycaemic effect of repaglinide were taken carefully into account in the studies, as 
discussed earlier. Recently, montelukast was shown to be metabolised mainly through 
CYP2C8 in vivo. Due to its better safety profile, similar sensitivity and maybe less complex 
interaction potential, montelukast may replace repaglinide as a probe drug for CYP2C8 
activity in the future (Karonen et al., 2011; VandenBrink et al., 2011). 
1.4. Pharmacokinetic modelling 
 
The gemfibrozil dose-proportionality was assessed using the power-model approach, which is 
currently considered as the method of choice (Sheng et al., 2010). In the single-dose study 
(III), the gemfibrozil and gemfibrozil 1-O-β-glucuronide AUC0-∞ data were used in the 
modelling, whilst for the data from the multiple dose study (IV) extrapolations of the AUC of 
the dosing interval (AUC0-12h) calculated using the last measured concentration C10h and ke 
were utilised. 
 
The static inhibitory models used for the data obtained in studies III and IV have been 
developed for predicting interactions in steady state conditions. Based on the half-life of 
gemfibrozil and its glucuronide, a steady state was achieved in study IV with a 5-day course 
of gemfibrozil. On the contrary, in study III using a single dose of inhibitor, a steady state was 
not achieved. Therefore, the application of the steady state models to this data could be 
argued. However, when comparing the findings of studies III and IV, the only difference was 
that the Ch,u/Cp,tot ratio was 3.2 times bigger in study IV than in study III indicating that the 
strong inhibition of CYP2C8 was obtained with lower gemfibrozil 1-O-β-glucuronide 
concentrations and lower gemfibrozil doses in study IV than in study III. Thus, the main 
result, the estimate of CYP2C8 inhibition with different gemfibrozil doses, was in line with 
the expectations that a steady state of mechanism-based inhibition is reached slowly with low 
inhibitor doses. Although physiologically based pharmacokinetic (PBPK) modelling of drug 
interactions in general provides advantages compared to static models by taking the changes 
in inhibitor, substrate and enzyme concentration over time into account, for mechanism-based 
inhibition, static models can be even more predictive than dynamic models (Einolf, 2007). 
However, as the more sophisticated dynamic, PBPK models are currently rapidly evolving, 
this may change in the future. 
 
In the models, previously published CYP2C8 and OATP1B1 inhibition constants for 
gemfibrozil and gemfibrozil 1-O-β-glucuronide were used. Corrections for microsomal 
binding were used, when appropriate. For OATP1B1 inhibition, a published IC50 for 
cerivastatin uptake was used, as inhibition constants for repaglinide uptake were not available. 
As OATP1B1 inhibition by gemfibrozil has been shown to be substrate-dependent (Noé et al., 
2007), better estimates in the analyses could have been achieved by the use of repaglinide 
specific inhibition constants. The OATP1B1 inhibition constant (for cerivastatin) used in the 
modelling was obtained by halving the IC50 value, in order to avoid underestimation of the 
contribution of OATP1B1 inhibition, if any, from the in vivo AUC ratio data (Hinton et al., 
2008). Despite these facilitative approaches, the OATP1B1 inhibition was estimated to be a 
minor contributor in the observed repaglinide-gemfibrozil interaction. This provides further 
evidence that this interaction is mainly due to inhibition of CYP2C8. 
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1.5. Generalisation of the data obtained 
 
Further, it can be argued whether the data obtained from these drug-drug interaction studies 
conducted in healthy volunteers can be generalised to patients. Drug metabolism and 
pharmacokinetics may indeed be altered by at least certain pathologic conditions, e.g., hepatic 
diseases or diabetes (Palatini et al., 2010; De Moraes et al., 2011). According to the current 
knowledge, the effects of reversible inhibition may be diminished, but the effects of 
mechanism-based inhibition are mostly retained in the patients with hepatic diseases (Palatini 
et al., 2010). In addition, the generalisation of the data to other CYP2C8 substrates could be 
questioned. The CYP2C8 inhibitory potential was suggested to be the most important factor 
in the repaglinide-gemfibrozil interaction with only a small contribution of OATP1B1 
inhibition. Therefore, besides for IVIVE and the design of clinical CYP2C8-mediated drug-
drug interaction studies, the data from these studies are considered adequate for guiding the 
management of drug-drug interaction potential of other CYP2C8 substrates in clinical use. 
 
2. Effect of time on mechanism-based inhibition of CYP2C8 by gemfibrozil 
 
In most previous clinical drug-drug interaction studies with gemfibrozil and repaglinide, the 
last dose of gemfibrozil pretreatment had been given 1 h before repaglinide. Simultaneous or 
very close administration of the inhibitor and substrate drug is adequate for achieving and 
maintaining the inhibitor concentrations during the exposure to the substrate drug. However, 
mechanism-based inhibition requiring a catalytic step before inactivation has been believed to 
occur more slowly than reversible inhibition. For studying the onset of mechanism-based 
CYP2C8 inhibition single doses of gemfibrozil 600 mg were given to healthy volunteers 
simultaneously with, and 1, 3 and 6 h before repaglinide. The pharmacokinetic variables of 
repaglinide and its metabolites (especially the M4/repaglinide AUC0-3h ratio) showed a rapid 
onset of CYP2C8 inhibition. Repaglinide geometric mean AUC0-∞ increased by 5.0-, 6.3-, 
6.6- and 5.4-fold and Cmax by 1.4-, 2.1-, 2.1- and 2.0-fold compared to control when 
gemfibrozil was given simultaneously with, or 1, 3 or 6 h before repaglinide. These and the 
pharmacokinetic variables of repaglinide metabolites suggested that the interaction between 
gemfibrozil and repaglinide develops in 1 h after a single dose of gemfibrozil reaching its 
maximum with a time interval of 1-3 h. This rapid onset was surprising, as several steps, e.g., 
absorption, transport and metabolism of gemfibrozil and a catalytic cycle of gemfibrozil 1-O-
β-glucuronide by CYP2C8 are required before the inhibition of the enzyme can occur. In fact 
the data showed already some recovery of the enzyme activity when the dosing interval was 6 
h. The information concerning the development of mechanism-based inhibition in humans can 
be used in the design of future clinical drug-drug interaction studies. Also, this rapid onset of 
a potentially hazardous interaction needs to be recognised for safer use of drugs in patients. 
 
Before this study, the inhibitory effect of gemfibrozil on repaglinide metabolism had shown to 
persist at least 12 h after the last gemfibrozil dose (Tornio et al., 2008a). This finding 
provoked the idea of a study design of even longer dosing intervals. In study II, dosing 
intervals of 1, 24, 48 and 96 h were used. The geometric mean AUC of repaglinide was 8.2-, 
3.0-, 1.4- and 1.0-fold compared to control, respectively; i.e., repaglinide metabolism was 
shown to be recovered back to the control level in the longest 96 h dosing interval. This was 
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supported also by the M4/repaglinide AUC data, which reflects the remaining CYP2C8 
activity. From the data from study II, the first-order degradation rate constant kdeg and t1/2 of 
CYP2C8 could be calculated from human in vivo data for the first time. Previously, only in 
vitro estimations of these variables had been published. The t½ calculated from study II (22 h) 
was in good agreement with the corresponding in vitro estimations (8-41 h (Renwick et al., 
2000)). In addition, the kinact/kdeg ratio of mechanism-based CYP2C8 inhibition by gemfibrozil 
1-O-β-glucuronide can be estimated at 380 based on the kdeg obtained. The in vivo kdeg for 
CYP2C8 can be used in future in vitro - in vivo extrapolations of interactions caused by the 
mechanism-based inhibition of CYP2C8. 
 
Based on these studies assessing the effects of dosing time on CYP2C8 inhibition caused by 
gemfibrozil, suggestions for better tolerated concomitant clinical use of gemfibrozil and 
CYP2C8 substrate drugs in patients could be given. If CYP2C8-dependent substrate drugs, 
particularly those with a narrow therapeutic index (if the use with gemfibrozil is not 
contraindicated), are started during the first 1-3 days after stopping gemfibrozil treatment, the 
reduction of their doses should be considered. However, it should be kept in mind that, e.g., 
the concomitant use of gemfibrozil and repaglinide is contraindicated in patients in many 
countries. 
 
3. Dose-dependency of mechanism-based inhibition of CYP2C8 by 
gemfibrozil 
 
With increasing oral gemfibrozil doses the AUC of gemfibrozil and gemfibrozil 1-O-β-
glucuronide increased more than dose-proportionally. The β value in the power model 
approach equation AUC = eα · doseβ was estimated at 1.21 and 1.16 for gemfibrozil in the 
single (III) and multiple (IV) dose studies, respectively. The corresponding value for 
gemfibrozil 1-O-β-glucuronide was estimated at 1.33 in both studies. This finding of more 
than dose-proportional pharmacokinetics may not have any clinical implications, but can be 
used in the estimations of the inhibitory potential of different gemfibrozil doses and in the 
design of clinical drug-drug interaction studies. 
 
The repaglinide AUC increased dose-dependently by increasing doses of gemfibrozil both in 
the single (III) and multiple (IV) dose study. The repaglinide geometric mean AUC0-∞ was 
increased by 1.7-, 4.3-, 6.5- and 8.1-fold compared to control when given 1 h after a single 
dose of 30, 100, 300 or 900 mg of gemfibrozil. The fold change observed in the highest 900 
mg dose phase was of the same extent as seen in previous studies with 600 mg twice daily for 
3 days, i.e., almost a maximal interaction level could be obtained. In the multiple dose study, 
repaglinide geometric mean AUC0-∞ increased by 3.4-, 5.5- and 7.0-fold of control after a 5-
day pretreatment with gemfibrozil 30, 100 or 600 mg twice daily. 
 
The repaglinide-gemfibrozil interaction, as described by the increase in repaglinide AUC and 
the decrease in the M4/repaglinide AUC ratio, is more potent during multiple dosing of 
gemfibrozil. This can be seen particularly in the smallest dose range studied (30-100 mg). 
This reflects the gradual increase in the loss of enzyme activity, which is typical for 
mechanism-based inhibition. At the largest gemfibrozil dose range such a great increase in the 
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extent of the interaction cannot be seen, as the large gemfibrozil doses are able to cause 
almost a maximal interaction already at single doses, and therefore, more potent inhibition 
during multiple dosing is not possible. 
 
When different individual inhibition models were fitted to the observed interaction data from 
both studies, the best fit was obtained by the mechanism-based inhibition model. A slightly 
better fit was obtained for the data in the single dose study than in the multiple dose study 
(r2=0.79 vs. 0.63), although the models have been developed to be used for steady state 
situations. For the data from both studies, a slightly better fit to the models could be obtained 
by adding a competitive OATP1B1 inhibition component to the CYP2C8 mechanism-based 
inhibition model. In both models concentration of gemfibrozil 1-O-β-glucuronide was used as 
the inhibitor concentration. 
 
Several predictions were made using different inhibition mechanism models both in separate 
and combined manner by using different inhibitor concentrations in the equations. Models 
using gemfibrozil 1-O-β-glucuronide as the inhibitor yielded better fits than those using 
gemfibrozil as the inhibitor concentration. This could be expected, because the inhibitory 
effect of gemfibrozil on CYP2C8 has been shown to be much weaker than that of gemfibrozil 
1-O-β-glucuronide (Shitara et al., 2004). Interestingly, for CYP2C8 inhibition mechanisms, 
better fits to the data were obtained by using Cavg than Cmax in the equations. This was also the 
case in the models assuming mechanism-based inhibition, although in literature, for 
mechanism-based inhibition, Cmax has been reported to be more predictive than Cavg (Obach et 
al., 2007; Obach, 2009). 
 
Based on these models, the fraction of the repaglinide dose metabolised by CYP2C8 was 84-
89% in the studies. This is somewhat more than estimated in previous studies (0.49-0.61) 
(Hinton et al., 2008; Baer et al., 2009), but in good agreement with the profound in vivo 
increases in repaglinide AUC after treatment with a strong CYP2C8 inhibitor gemfibrozil. 
The repaglinide fraction transported by OATP1B1 was estimated at 94% and 15% based on 
the data of the single and multiple dose studies. With single dosing, the OATP1B1 inhibition 
contributes to some extent to the observed interaction. However, when multiple dosing is used 
the mechanism-based inhibition of CYP2C8 is so strong that the contribution of OATP1B1 
inhibition is smaller. The differences in the estimates of ft,OATP1B1 can also be explained by the 
low specificity of the model for OATP1B1 inhibition. The IC50 value of cerivastatin uptake 
instead of that of repaglinide uptake was used and the reported IC50 value of cerivastatin was 
halved in order to avoid underestimation. A repaglinide specific IC50 value, if available, would 
therefore make the predictions more precise. In addition, when analysing more than one 
inhibition method concomitantly, a dynamic model might also improve the predictions. 
 
The gemfibrozil 1-O-β-glucuronide Ch,u/Cp,tot was predicted at 0.24-0.86 with the best fitting 
models in the studies, i.e., the total plasma concentrations of gemfibrozil 1-O-β-glucuronide 
would be 1-4 -fold compared to its hepatic unbound concentrations. As gemfibrozil 1-O-β-
glucuronide is known to concentrate in the liver in rats (Sallustio et al., 1996), and 
considering the plasma fraction unbound (fu; 0.115) of gemfibrozil 1-O-β-glucuronide, this 
level of accumulation can be regarded as possible. When other than CYP2C8 mechanism-
based inhibition models were used, the predicted Ch,u/Cp,tot values were much higher. In that 
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case higher intrahepatic gemfibrozil 1-O-β-glucuronide concentrations are needed for potent 
inhibition. The estimate of Ch,u/Cp,tot based on the mechanism-based inhibition model was 3.2 
times higher in the multiple dose study (IV) than in the single dose study (III). The estimate 
based on study IV is likely to be more reliable, because the design in study III violated the 
assumption of steady-state conditions, while the inhibitor concentrations in study IV were 
very close to steady-state. If the Ch,u/Cp,tot estimated in study IV was true, the average 
unbound gemfibrozil 1-O-β-glucuronide concentrations in the hepatocyte would be 
approximately 14 µM with twice daily dosing of 600 mg gemfibrozil. After administration of 
a single 600 mg gemfibrozil dose, the unbound gemfibrozil 1-O-β-glucuronide concentrations 
in the hepatocyte are likely to be almost as high as after multiple dosing. According to in vitro 
data (Niemi et al., 2003b; Ogilvie et al., 2006), a 10 µM gemfibrozil 1-O-β-glucuronide 
concentration in the hepatocytes could lead to ~90% inactivation of CYP2C8 in 40-120 
minutes, which is sufficiently rapid to explain the rapid inactivation observed after a single 
600 mg gemfibrozil dose in Study I. Therefore, the results from these studies assessing both 
time and dose relationships of mechanism-based inhibition of CYP2C8 by gemfibrozil are in 
good agreement with each other. 
 
The mechanism-based inhibition of CYP2C8 by gemfibrozil was shown to be clearly dose-
dependent. With increasing gemfibrozil doses, both in the single and multiple dosing 
schemes, the extent of the inhibition increased. A level of ~50% inhibition of the CYP2C8 
activity could already be obtained by a single 30 mg dose of gemfibrozil or by twice daily 
administration of << 30 mg of gemfibrozil. > 90% of the CYP2C8 activity could be inhibited 
by a single dose of 900 mg or twice daily dosing of 100 mg gemfibrozil.  
 
4. General discussion and future prospects 
 
Drug-drug interactions may cause severe consequences on drug efficacy and patient safety. 
Therefore, the detection, evaluation, understanding and management of the drug-drug 
interaction potential of therapeutic agents are essential. Drug-drug interaction potential can 
currently be studied by in vitro, in vivo and in silico methods. Of several possible mechanisms 
leading to drug-drug interactions, the interactions based on metabolic enzyme inhibition are 
often regarded as of great clinical importance. 
 
The clinical importance of metabolic enzyme inhibition is based on, e.g., the fraction of the 
victim drug metabolised with the enzyme concerned (fm) and the therapeutic index of the 
victim drug. Drugs which are mainly metabolised with the inhibited enzyme and which have a 
narrow therapeutic index may cause severe adverse reactions in clinical use, when 
administered concomitantly with an enzyme inhibitor. The knowledge of metabolic pathways 
of the drugs and their relative fractions are therefore important in drug development. In in 
vitro - in vivo extrapolations, the ratio of clinical drug concentrations and the concentration 
supporting half of the maximal inhibition is essential.  
 
In the case of mechanism-based inhibition, the extrapolation of in vivo consequences is even 
more complex. The fraction metabolised with the enzyme concerned, therapeutic index and 
the in vivo drug concentrations of the substrate drug, as well as the inhibitor potency are 
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important also in this interaction mechanism. In addition, the ratio of the rate of enzyme 
inactivation (kinact) and the first order degradation rate of the inhibited enzyme (kdeg) impact 
the clinically observed interaction. A high kinact/kdeg ratio can make the mechanism-based 
inhibition clinically significant, although the [I]/KI ratio would be fairly small. 
 
Before this thesis work, gemfibrozil was recognised as an important CYP2C8 inhibitor; it was 
recommended as a model inhibitor of CYP2C8 for drug development (FDA, 2006). Also, the 
importance of CYP2C8-mediated interactions in clinical drug therapy had recently been 
acknowledged, as the list of CYP2C8 substrate drugs has continuously increased. The 
mechanism-based nature of CYP2C8 inhibition by gemfibrozil 1-O-β-glucuronide and the 
extent of repaglinide-gemfibrozil interaction were already known (Niemi et al., 2003b; 
Ogilvie et al., 2006). The in vivo time and dose relationships of this interaction, as those of 
many interactions caused by mechanism-based inhibition, were fairly unexplored. 
 
This work provides new data concerning the turnover half-life of CYP2C8 and the onset, 
persistence and dose-dependency of CYP2C8 inhibition by gemfibrozil, which will help the 
in vitro –in vivo extrapolation of drug interactions caused by the mechanism-based inhibition 
of CYP2C8 and guide the design of clinical drug-drug interactions, at least with regard to the 
dosing and timing of gemfibrozil administration.  
 
Based on the pharmacokinetic modelling made in this work mechanism-based CYP2C8 
inhibition was suggested to be the main component behind repaglinide-gemfibrozil 
interaction. The data of two dose-related studies were modelled separately, and mechanism-
based inhibition was proposed to be the main component by the results of both of them. 
However, the results of these studies propose small additional effects of other mechanisms as 
causal components in the observed clinical interaction. With a static model using only data 
from one study separately the different interaction mechanism could not be quantified very 
well. One reason for this is probably the fact that the inhibitory potencies of the mechanisms 
are different, i.e., the contribution of the less-potent mechanisms could not be separated and 
quantified behind the mechanism-based inhibition of CYP2C8. The modelling of the 
interaction mechanism would be more powerful and provide more precise data, if data from 
different repaglinide-gemfibrozil studies with different dosing and timing schemes would be 
pooled, and analysed together using dynamic, physiologically-based pharmacokinetic models. 
 
The repaglinide-gemfibrozil interaction was proposed to be mainly due to the effects of 
gemfibrozil 1-O-β-glucuronide, the metabolite of gemfibrozil. In addition to the suggestion of 
mechanism-based inhibition being the main component of this interaction, this work provides 
confirmation of the importance of safety evaluation of metabolites, an issue which has gained 
attention in drug development (Baillie et al., 2002; Atrakchi, 2009; EMA, 2010; Parkinson et 
al., 2010; VandenBrink and Isoherranen, 2010). 
 
This work has also clinical implications. To enable safe use of drugs, information concerning 
the onset and persistence of drug-drug interactions is crucial. Although the clinical use of 
gemfibrozil has decreased, there are still patients, who may benefit from the lipid-lowering 
effects of gemfibrozil. Safety margins for starting and stopping concomitant administration of 
gemfibrozil and CYP2C8 substrates were obtained by this work, which further supports 
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earlier findings that caution should be exercised when gemfibrozil is used concomitantly with 
substrates of CYP2C8. It should be noted, that concomitant administration of gemfibrozil and 
some CYP2C8 substrates such as repaglinide is contraindicated in some countries. 
 
One additional future prospect of this work is related to the intentional modification of 
pharmacokinetics of drugs. The bioavailability of drugs with substantial CYP2C8-mediated 
first-pass metabolism could be increased by using small gemfibrozil doses similarly as 
proposed previously for agents metabolised by other enzymes (Sellers et al., 2000). In 
addition, the formation of CYP2C8-mediated toxic metabolites of therapeutic drugs could 
possibly be reduced by gemfibrozil administration. E.g., neurotoxicity, which is currently the 
dose-limiting issue in the clinical use of the antineoplastic agent paclitaxel, has been shown to 
be associated with the CYP2C8 genotype (Mielke et al., 2005; Gréen et al., 2008; Leskelä et 
al., 2011). If the CYP2C8-dependent paclitaxel metabolites are shown to be more neurotoxic 
than the CYP3A4-dependent metabolites, as currently thought, one therapeutic option in 
cancer patients receiving paclitaxel is to inhibit CYP2C8 by a small gemfibrozil dose thereby 
forcing paclitaxel to CYP3A4-mediated metabolism routes. This could be done by a separate 
formulation of gemfibrozil or a combined paclitaxel-gemfibrozil formulation. As new drugs 
are continuously recognised as being dependent on CYP2C8-mediated metabolism, there 






The following conclusions can be made based on the studies in this thesis: 
 
 
1. Mechanism-based inhibition of CYP2C8 by gemfibrozil occurs rapidly in humans. 
The inhibitory effect developed to its maximum already in 1-3 h after gemfibrozil 
intake. 
 
2. CYP2C8 inhibition after gemfibrozil treatment abates slowly. A full recovery of 
CYP2C8 activity, as measured by repaglinide metabolism, was achieved 96 h after 
cessation of gemfibrozil treatment. If CYP2C8-dependent substrate drugs, particularly 
those with a narrow therapeutic index (if the use with gemfibrozil is not 
contraindicated), are started during the first 1-3 days after stopping gemfibrozil 
treatment, the reduction of their doses should be considered. 
 
3. Mechanism-based inhibition of CYP2C8 by gemfibrozil was shown to be dose-
dependent. With increasing doses, both in single and multiple dose schemes, the 
extent of the inhibition increased. It was estimated that a level of ~50% inhibition of 
the CYP2C8 activity could already be obtained by a single 30 mg dose of gemfibrozil 
or by twice daily administration of << 30 mg of gemfibrozil. Further, > 90% of the 
CYP2C8 activity could be inhibited by a single dose of 900 mg or twice daily dosing 
of approximately 100 mg gemfibrozil.  
 
4. The first-order degradation rate constant of CYP2C8 in humans is estimated at 
0.00056 min-1 and the corresponding CYP2C8 enzyme turnover half-life at 22 h. 
These values can be used in the prediction of interactions caused by the mechanism-
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